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HLA-B27 molecules show a remarkable association with ankylosing spondylitis (AS), 
reactive arthritis (ReA) and other spondyloarthropathies (SpA), but the mechanism 
remains a mystery. There are experimental evidences supporting the hypothesis of an 
‘arthritogenic’ peptide which induces an anti-self response. Peptide specificity 
modulated by HLA-B27 polymorphism may be a key to the linkage of HLA-B27 
subtypes to disease. The objectives of this project are to define the effects of 
variability at the peptide C-terminal anchor residue on its binding to differential 
disease associated HLA-B27 subtype (HLA-B*2702, B*2703, B*2704, B*2705, 
B*2706, B*2707, B*2709) and explore the linkage between the disease association 
and peptide-binding specificity.  
By using reverse transcription - polymerase chain reaction (RT-PCR), the cDNA 
which encode the whole reading frame of HLA-B*2702/04/05/06 heavy chain protein 
were obtained from EBV-transformed B-Lymphoblastoid cell lines. RT-PCR products 
were first cloned into pCR-TOPO2.1 vector by using TA cloning, then subcloned into 
plasmid pET30-BirA for protein expression. The plasmid constructs pET30-BirA-
HLA-B*2703/07/09 which encode HLA-B*2703/07/09 heavy chain protein were 
generated by site-directed mutagenesis from construct pET30-BirA-B*2705. 
The different HLA-B27 subtype heavy chain and light chain (β2-microglobulin) 
protein were over-expressed in E. coli as an inclusion body and solubilized in 8M Urea. 
The in vitro refolding method was carried out to reconstitute the HLA-B27/peptide 
complex using the recombinant HLA-B27 heavy chain, β2m and peptide. HLA-
B*2705 heavy chain, β2m and peptide GRAFVTIGK were reconstituted and the 
complex was analyzed by FPLC gel filtration. A peptide dependent peak was appeared 
 VIII
on gel filtration chromatography. SDS-PAGE analysis revealed that the peak was 
composed of the HLA-B27 heavy chain and β2m protein. The reconstituted HLA-
B27/peptide complex was recognized by HLA-A, -B, -C conformation specific mAb 
W6/32, demonstrating that HLA-B27/peptide complex can be reconstituted by 
refolding method and the reconstituted complex was correctly folded.  
Finally, peptide GRAFVTIGK and its P9 substituted analogues were used to 
investigate the effects of variability at the C-terminal anchor residue on its binding 
affinity to HLA-B27 subtypes and western blotting was carried out. The results 
showed that non-polar amino acids are clearly preferred at the C-terminal anchor. 
B*2702, B*2704 and B*2705 which are positively associated with ankylosing 
spondylitis bound C-terminal tyrosine strongly, while B*2706 and B*2709 which are 
negatively associated with disease displayed poor affinity for C-terminal tyrosine. 
Overall, the pattern of in vitro refolded HLA-B27/peptide complexes showed 
remarkable agreement with known data derived from mass spectrometry analysis of 
recovered naturally bound peptide ligands. Our data also suggest that HLA-B27 
structural polymorphism have relatively moderate influences on binding specificity at 
the P9 anchor, and most subtypes can bind the same peptides with similar binding 
affinity.   
In summary, our study has defined some major rules governing P9 residue preference 
of seven HLA-B27 subtypes and has described how these features are modulated by 
B27 polymorphism. This study provides evidence that in vitro refolded HLA-peptide 
interactions mimic that of the natural peptide ligand pool and also demonstrates the 
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1.1 Molecular genetics of Human Leukocyte Antigens (HLA) molecules 
The human leukocyte antigens (HLA) or human major histocompatibility complex 
(MHC) region is a set of closely linked genetic loci that encode a number of different 
molecules. It spans approximately 4 megabase (Mb) of DNA (~1% of the genome) on 
the short arm of chromosome 6 at 6p21.3 (Campbell and Trowsdale, 1993). More than 
220 genes have been located in the HLA region and at least 10% of these have 
functions related to the immune system. The human MHC is traditionally divided into 
the class I, class II and class III regions. (Figure 1.1). The HLA class I region, at the 
telomeric end of the complex, encompasses almost 2Mb and contains genes encoding 
for HLA class I molecules. The class II region is at the centromeric end of the complex 
and encompasses 1Mb containing genes encoding for HLA class II molecules. It also 
contains other genes important in antigen processing and presentation. The class III 
region, lying between the other two clusters, encompasses 1100Kb of DNA and 
contains a number of genes with a variety of functions. 
 
1.1.1 HLA class I region 
The classical HLA class I region contains three main functional loci, HLA-A, HLA-B 
and HLA-C (Lawlor et al., 1990). Each of these genes encodes α-chain of the class I 
molecules. These genes are expressed on most somatic cells, but with varying levels in 
different tissue and cell types, even within a given organ (Klein, 1986). These genes 
are highly polymorphic and have important roles in cellular immunology. HLA class I 
molecules have the ability to present peptides to cytotoxic T lymphocytes (CTLs). In 
addition to this main role, the expression of class I molecules at the cell surface can 
have other important effects. For example, they appear to be expressed selectively on 































Figure 1.1. Schematic map of the human major histocompatibility complex. The 
complex is conventionally divided into three regions: class I, II and III region. Each 
region contains numerous genes, only some of which are shown.  
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immunosurveillance by cytotoxic T cells on to functionally impaired neurons 
(Neumann et al., 1995). Lack of class I expression at the materno-fetal interface 
(villous and extravillous cytotrophoblast and syncytiophoblast) may facilitate survival 
of the fetal tissue as an allograft in the maternal host (Trowsdale, 1996). Additionally, 
there is increasing evidence for a role of HLA-C in target recognition by natural killer 
(NK) cells (Colonna et al., 1993).  
Besides the three classical loci HLA-A, HLA-B and HLA-C, there are some non-
classical class I loci in the HLA class I region, including HLA-E, HLA-F and HLA-G 
(Geraghty, 1993). These genes, generally much less polymorphic than HLA-A, -B or –
C, lead to the production of class I-related molecules, of unknown function and 
restricted tissue distribution. Apart from these loci, the class I region contains at least 
12 pseudogenes or gene fragments that are closely related to the class I heavy chain 
genes: HLA-17, -X, -30, -L/92, -J/59, -80, -21, -K/70, -16, -H/54, -90 and -75 
(Geraghty 1993; Le Bouteiller, 1994).  
In addition to these HLA class I loci already described, a family of MHC class I chain-
related (MIC) genes was identified.  This family has two members (MICA and MICB) 
at the telomeric end of the class III region (Bahram et al., 1994) and further three 
related gene fragments MICC, MICD and MICE within the class I region (Bahram et 
al., 1996). The class I region still contains a large number of other genes which fall 
into many families and some of them have a potential role in immune system.  
 
1.1.2 HLA class II region  
The HLA class II region spans about 800kb of DNA and contains all of the known 
class II α- and β-chain genes. In human, the main surface-expressed molecules are 
HLA-DP, -DQ and –DR. The α- and β- chain genes are all arranged as matched pairs 
(i.e. DRA and DRB, DQA and DQB, DPA and DPB) but the number of DRB genes 
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and pseudogenes varies depending on the haplotype (Rollini et al., 1985; Andersson et 
al., 1987; Gorski et al., 1987; Kawai et al., 1989). Both the DQ and DP regions 
include paired pseudogenes (DQA2 and DQB2, DPA2 and DPB2), although the DQ pair 
of sequences does not contain any obvious deleterious coding region mutations 
(Trowsdale et al., 1984; Gustafsson et al., 1987; Jonsson et al., 1987).  
The class II region contains two other pairs of class II genes, HLA-DNA and –DOB, 
whose products form a heterodimeric protein, HLA-DO (Tonnelle et al., 1985; Young 
and Trowsdale, 1990; Karlsson et al., 1992). HLA-DMA and –DMB are two linked 
genes that are only distantly related to other class II sequences and show relatively 
little polymorphism (Cho et al., 1991; Kelly et al., 1991a). The putative structure of 
the DM molecule is similar to that of classical class II molecules.  
In the HLA class II region there are also a tight cluster of genes located between the 
HLA-DQ and –DP subregions. The products of the two TAP (transporter associated 
with antigen processing) genes, TAP1 and TAP2, are members of the ABC (ATP-
binding cassette) transporter superfamily (Townsend and Trowsdale, 1993). The 
products of the two TAP genes form a complex in the endoplasmic reticulum (ER) 
membrane which translocates peptides from the cytoplasm into the lumen of the ER 
(Androlewicz and Cresswell, 1994). In the vicinity of TAP, there are two additional 
genes also involved in class I antigen processing called LMP2 and LMP7. These two 
genes encode components of the proteasome complex (Glynne et al., 1991; Kelly et al., 
1991b; Goldberg, 1995). 
Besides all of the genes in the class II region described above, there are also a lot of 







1.1.3 HLA class III region 
The class I and class II regions are separated by the central class III region that spans 
1100kb segment of DNA (Figure 1.1). The class III region also contains genes that 
encode proteins with important known immune-related functions such as the 
complement components C2, C4 and Factor B, and cytokines tumor necrosis factor 
(TNF), and lymphotoxin (LT) α and β.  
 
1.1.4 Polymorphism of the HLA 
There are several interesting features in the region of HLA genome. The most 
important one is the extraordinary allelic variation shown by the loci encoding HLA 
molecules, by far the most polymorphic human proteins known. According to the 
WHO Nomenclature Committee latest update, there are currently 290 HLA-A, 553 
HLA-B and 140 HLA-C alleles in the class I loci. All of the HLA products are 
polymorphic to a greater or lesser extent, with the exception of the DRα chain. This 
chain does not vary in sequence between different individuals and is said to be 
monomorphic (Marsh and Bodmer, 1995). There are numerous alleles present in the 
population at each locus except DRA, and most normal outbred individuals are 
heterozygous at most loci.  
The mechanisms by which the polymorphism arises are also important. Although point 
mutations cause the generation of new alleles during evolution, HLA allelic variation 
is often the result of recombination, and most notably gene conversion or 
nonhomologous recombination (Trowsdale, 1996). These events can happen even 
between different loci in the HLA region. There is a case for the coevolution of 
combinations of alleles at different HLA loci, in the form of haplotypes (Trowsdale, 
1996). The fact that there is strong linkage disequilibrium over extended haplotype 
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suggests the existence of selective pressure to maintain certain haplotypes or 
combinations of alleles from different HLA loci.  
In the case of HLA class I and class II molecules, most of the sequence differences 
between the different alleles are concentrated in the peptide binding site and the site of 
interaction with the T-cell receptor (Parham et al., 1988). Therefore different MHC 
molecules have different pockets composition and bind peptides with different residues 
(or motifs). The particular peptide sequences depend, of course, on the individual HLA 
alleles. Thus the immune response can vary from one individual to another.  
The existence of multiple HLA alleles is beneficial for the population. Pathogens have 
a number of possible strategies for avoiding an immune response either by evading 
detection or by suppressing the ensuring responses. The requirement for presentation 
by a HLA molecule provides at least one possible means of evasion. A given T cell 
only recognized viral peptide when they are bound to a specific HLA molecule 
(Zinkernagel and Doherty, 1974). The immune response is thus shown to be the HLA 
restricted and requires a combined signal from both HLA molecules and pathogen 
peptide. Some pathogens could escape detection by undergoing mutations that 
eliminate potentially antigenic peptides that contain motifs for common HLA 
molecules. This process of evasion of the immune response is plainly much more 
difficult for a potential pathogen if there are many different HLA molecules, and the 
presence of different loci encoding functionally related proteins may have been an 
evolutionary adaptation to this strategy. Because specific HLA-peptide combinations 
are required to elicit an immune response, individuals heterozygous at HLA loci would 
more effectively defend themselves from infections by responding to a broad range of 
pathogens (Doherty and Zinkernagel, 1975). Polymorphism has the additional 
advantage that different individuals in a population will differ in the combinations of 
Introduction 
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HLA molecules they express and will thus present different sets of peptides from each 
pathogen. This makes it unlikely that all individuals in a population will be equally 
susceptible to any given pathogen, thereby limiting its spread. 
 
1.2 HLA class I genes and molecular structure 
 
1.2.1 HLA class I gene exon-intron organization  
The HLA class I α-chain gene is composed of 8 exons and 7 introns (Figure 1.2) 
(Koller, et al., 1985). The first exon codes for a leader sequence. Exon 2 to 4, 
separated by introns of various lengths, encode the α1, α2 and α3 domain of the HLA 
class I molecules, respectively. Exon 5 encodes the hydrophobic transmembrane 
segment. This exon also encodes a 5 amino acids hydrophilic peptide, which is the 
beginning of the cytoplasmic segment. The remainder of the cytoplasmic region is 
cytoplasmid region which is encoded in exons 6 and 7. Exon 8 contains the nucleotides 
of the COOH-terminal valine codon, the termination codon, and the 3' untranslated 
region.  
 
1.2.2 HLA class I molecule structure 
HLA class I molecules are composed of two polypeptide chains called heavy chain or 
α chain and light chain or β chain (Figure 1.3) (Bjorkman et al., 1990). The heavy 
chain or α chain, encoded with the HLA region, is a transmembrane glycoprotein with 
a molecular weight of approximately 45kDa (encoded in the HLA region), oriented 
with its N-terminal major portion on the outside of the cell. The extracellular portion of 
the heavy chain has been divided into three subdomains called α1, α2 and α3 
(Tragardh, et al., 1979) composed of 90, 92 and 92 amino acids, respectively 
(Malissen, et al., 1982). α1 and α2 domains are distal to the cell membrane and α3 
Introduction 
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domain is proximal to it. Following the α3 domain is a membrane-spanning region of 
























Figure 1.2. Exon-intron organization of HLA class I gene and its encoded 
protein. EX, exon; L, leader peptide; UT, untranslated region; α1, α2 and α3, 
three extracellular domains of HLA class I heavy chain; Tm, transmembrane 
region; and Cy, cytoplasmic portion. The number below the schematic diagram 
of heavy chain represents the heavy chain amino acid residues. 
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Figure 1.3. Schematic diagram of HLA class I molecule. Class I molecules 
contain a large α-chain non-covalently associated with the light chain β2-
microglobulin. The α-chain is composed of three portions: extracellular, 
transmembrane and cytoplasmic region. The extracellular region consists of three 




The light chain or β chain is called β2-microglobulin (β2m), encoded by the beta 2-
microglobulin gene, which is outside the HLA region and on chromosome 15. This 
non-HLA-encoded protein with a molecular weight of 12 kDa non-covalently binds to 
heavy chain (Grey, et al., 1973; Peterson, et al., 1974). Both the α3 and β2m domain 
have conserved immunoglobulin-like domain structure.  
The detail three-dimensional structures of some HLA class I molecules have been 
determined by X-ray crystallography (Bjorkman et al., 1987a; Garboczi et al., 1992; 
Madden et al., 1992). All of the molecules have similar structures (Figure 1.4). The N-
terminal α1 and α2 domains fold together to form the peptide-binding groove, which is 
a platform with an eight-stranded β-pleated sheet topped by two long α helices. Each 
of the α1 and α2 domains accounts for one of the α helices and four of the β-plated 
strands. Between the two α helices and the floor of the β sheets there is an empty space. 
It is in this space or “groove” where the foreign peptide fits. The peptide binding 
groove is not a homogeneous space. It contains smaller subgrooves known as pockets 
which accommodate the side chains of the amino acid residues of peptides bound 
within the groove (Bjorkman et al., 1987a; Garrett et al., 1989; Matsumura et al., 
1992). HLA class I peptide binding groove is generally divided into six pockets 
denoted A-F (Figure 1.5) (Engelhard, 1994), although pocket structure varies 
significantly between different alleles. It is the sequence of the HLA molecule itself 
which determines the properties of the “pockets” and thus determines peptide 
specificity. Individual HLA alleles can differ from one another by up to 20 amino acids, 
making each allele quite distinct. Most of these differences are localized to the exposed 
surfaces of the membrane-distal domains of the molecule, and to the peptide-binding 
groove in particular. Crystal structures of HLA class I molecules reveal that 





























Figure 1.4. Ribbon diagram showing the three-dimensional structure of HLA 
class I molecule. The α chain is shown in blue, β2 in green and the bound peptide in 
red. (A): End view looking down the peptide binding cleft, showing the α2 helix on 
the left and the α1 helix on the right over a platform of β sheet, forming a deep cleft 
in which the peptide sits. (B): Top view of the peptide binding cleft with the α1 
helix at the top and the α2 helix at the bottom lying over the platform. The α3 
domain andβ2m have been removed for clarity. (The figure was produced using 




































Figure 1.5: Schematic diagram of six pockets defined in the peptide-binding 
cleft of HLA class I molecules (top view of peptide-binding cleft). A, residues 
of HLA class I molecules identified by their amino acid position number.  B, the
peptide-binding site of HLA class I molecules contain six pockets of which some 
are involved in the binding of the peptides. The peptide (red) extends from the A-











influences the selection of antigenic peptides (Jardetzky 1996). The distinct structures 
of the pockets in different HLA class I alleles dictate a requirement for a distinct set of 
anchor residues, limiting the peptide to those which express an allele-specific sequence 
motif.  
When a peptide is bound to a HLA class I molecule, the exposed middle portion of the 
peptide, and HLA residues along the tops of the α1 and α2 domain helices form a 
planar surface that interacts with T cell receptors (Bjorkman et al., 1987a). α1 and α2 
domains are important for peptide binding, α3 and β2m domain also play important 
role. They interact with each other to maintain a proper structure of the HLA class I 
molecule. To increase the avidity between the T cell and the class I expressing target 
cell, the CD8 co-receptor molecule binds to the α3 domain of the class I molecules, 
probably to the same molecule to which the TCR is bound (Salter RD et al., 1990; 
Giblin et al., 1994).  
 
1.2.3 The conformation of bound peptides 
HLA class I molecules bind peptides in an extended conformation (Madden et al., 
1991; Matsumura et al., 1992), leaving the main chain atoms and termini of the 
peptides open for direct interactions with residues of the HLA molecule (Figure 1.6). 
The amino-terminus of the peptide lies to the left, near the N-terminal end of the α1 
helix and the C-terminal end of the α2 helix. This orientation of bound peptides seems 
to be the same for different HLA class I molecules. Three residues at the amino-
terminus and two residues at the C-terminus of bound peptides adopt an essentially 
invariant conformation in the HLA class I binding site (Madden et al., 1992; 
Matsumura et al., 1992), while the central residues of the peptide can be more flexibly 
accommodated within the peptide-binding site. For example, for the structures of five 
individual peptide-HLA-A2 structures (Madden et al., 1993), the N- and C-terminal 
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residues of these peptides show a common conformation, while the central residues 
























Figure 1.6. Interaction between HLA Class I Molecules and 
Peptides. A longitudinal section through the peptide-binding groove of 
an HLA class I molecule, the side chains of amino acid residues 
composing the bound peptide (P1 through P9) are oriented either down 




1.3 Cell biology of HLA class I molecules  
 
1.3.1 Peptide binding to class I molecules  
Peptide binding has been shown to be important for the stable folding of HLA class I 
molecules (Silver et al., 1991). The crystallographic structure of the HLA class I 
molecules showed that HLA molecules act as receptors for peptides to be presented to 
T cells (Bjorkman et al., 1987a & 1987b; Madden et al., 1991). This view was 
confirmed by subsequent experiments in which crystal structures of additional class I 
molecules were solved with a better definition. Soon after these observations were 
made, useful techniques were developed (Joyce et al., 1994) to isolate and characterize 
peptides which were naturally bound to class I molecules. Sequence determination of 
dominant peptides by Edman degradation and mass spectrometry have provided 
relevant information about the length and nature of peptides bound specifically to a 
number of class I alleles.   
The overall shape of the peptide-binding groove of the HLA class I molecules can 
accommodate peptides typically varying in length between 8-11 amino acids, although 
a subset of longer peptides can be found (Jardetzky, 1996). The ability of individual 
HLA class I molecule binding to different peptides is based on specific interactions 
involving up to six pockets in the peptide-binding groove, but for any given peptide 
not all of the pockets are necessarily occupied (Engelhard, 1994). It is these 
interactions that allow the HLA molecules to discriminate between peptides, binding 
some and not others. Peptide analogues with modified amino and carboxyl terminal 
groups fail to form stable complexes with HLA class I molecules (Bouvier et al., 1994; 
Bouvier et al., 1998). These conserved interactions dictate that the peptide termini lied 
at fixed positions along the peptide binding groove, placing a constraint upon the 
length of peptides that can be favorably bound. However, some class I molecules such 
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as Aw68 can bind longer peptides (up to 13 amino acids). These longer peptides are 
accommodated by a pronounced central kink of the peptide backbone, whereas the N- 
and C-terminal ends are buried into the peptide binding groove (Guo et al., 1992). 
Additionally, it has been shown that HLA-B27 binds also a considerable amount of 
much longer (up to 33 amino acids) peptides (Urban et al., 1994).  
It has been estimated that over 10,000 different peptides can be bound to cell surface 
class I molecules (Engelhard, 1994). Despite this diversity, class I-binding peptides 
contain sequence motifs defined by the position and the identity of conserved residues 
among the different peptides bound to a given class I allotype. These sequence motifs 
are most critical for the high affinity binding of peptides and have been termed anchor 
residues (Falk et al., 1991). These nonvariable residues can be deduced by sequencing 
unfractionated mixtures of peptide (pool sequencing) (Falk et al., 1991; Rammensee et 
al., 1993) previously eluted from a particular class I allotype. The alignment of amino 
acid sequences obtained from isolated individual peptides is also useful to identify 
conserved residues among different peptides (Rammensee, 1995). There is always 
limited variation in the peptide C-terminal residue, thus it is an anchor position for 
most class I molecules. In additional to the C-termini, another anchor is usually found 
at position 2, and less frequently at positions 3, 5 or 7 (Martinez-Naves and Setien 
Baranda, 1997). Additionally most of the other residues in the peptide can make 
contact with amino acids in the vicinity of the HLA groove. These additional 
interactions can be important to tune the fine peptide specificity of HLA molecules. 
Information of allele-specific motifs for peptide bound to different HLA allotypes is 
important to define T cell epitopes in proteins from infectious microorganisms such as 
viruses or bacteria, as well as tumor related antigens that are recognized by T cells. 
Definition of these epitopes could be very important in designing immunotherapy or 
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vaccination strategies against infectious agents, cancer, allergy or HLA-associated 
autoimmune diseases.  
 
1.3.2 Antigen processing and presentation 
Cytotoxic T lymphocytes (CTL) play an important role in the elimination of 
intracellular pathogens. A typical CTL response requires that receptors on the T-cell 
specifically recognize the target cell antigen derived from the pathogen bound to cell 
surface expressed MHC class I molecules (McMichael, 1996).  
HLA class I proteins bind peptides from proteins located in the cytosol and present 
them to mature CD8+ cytotoxic T cells. If the peptides bound to class I molecules are 
from endogenous proteins (self peptides), CTLs are not activated after the contact with 
the presenting cells. However, if the presenting cells are infected with intracellular 
pathogens (such as viruses or bacteria), peptides derived from the newly synthesized 
pathogen proteins are rapidly presented by class I molecules at the cell surface. In this 
case, CTLs are activated after detecting the presence of these non-self peptides. The 
activation of CTL response leads to the destruction of the infected cell, preventing the 
spread of the infectious intracellular agent. 
HLA class I molecules are specialized in binding peptides from cytosolic proteins, 
even if these proteins lack the signal sequence necessary to enter the endoplasmic 
reticulum (ER) (Townsend et al., 1985). The heavy chain rapidly associates with β2m 
in the ER after biosynthesis. The β2m is absolutely necessary for the proper folding of 
class I molecules. Heavy chains lacking β2m are retained and degraded in the ER. 
Properly folded class I-β2m complexes bind peptides already present in the ER. Only 
after the heavy chain-β2m complex is assembled with peptide is the whole structure 
able to exit the ER and reach the cell surface following the exocytic pathway common 
to other membrane and secretory proteins.  
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1.3.2.1 Peptide processing 
Cytosolic proteins must be degraded to produce suitable peptides before they are 
transported to the endoplasmic reticulum (ER) and loaded in class I molecules. In this 
process, proteases in the cytosol and the ER are important. Most of the protease 
activity in the cytosol is provided by the action of the proteasome, a large 
multicatalytic protease complex. Proteasomes have a broad proteolytic activity, 
degrading bonds on the carboxyl side of basic, hydrophobic and acidic residues 
(Goldberg and Rock, 1992). Two proteasomes subunits, LMP2 and LMP7 (Glynne et 
al., 1991; Brown et al., 1991; Martinez et al., 1991), encoded in the HLA region, 
strongly regulate the generation of class I binding peptides. In the cytoplasm, when the 
foreign protein is expressed, the antigen is degraded by the proteasome into short 
peptide fragments.  
 
1.3.2.2 Peptide presentation 
Peptides generated in the cytosol are unable to reach the endoplasmic reticulum (ER) 
passively. The peptide transportation needs the help of TAP protein (Transporter 
associated with Antigen Presentation). TAP is a heterodimer which consists of two 
polypeptides encoded by the TAP1 and TAP2, which are two closely linked genes 
located in the MHC class II subregion. TAP localizes mainly to ER and Golgi 
membranes (Kleijmeer et al., 1992). TAP heterodimers are physically associated with 
nascent β2m-heavy chain complexes (Ortmann et al., 1994; Suh et al., 1994). When 
peptides are generated, TAP transports peptides with appropriate size and composition 
into the ER and associate with HLA class I molecules. Once the whole complex, heavy 
chain, β2m and peptide is properly assembled in the ER, the HLA molecule dissociates 




1.4 HLA-B27 and disease pathogenesis 
HLA-B27 is a HLA class I gene product that was recognized as a new HLA specificity 
at the Fourth International Histocompatibility Workshop in 1970. HLA-B27, together 
with the HLA-A2 antigen, is among the best studied HLA class I antigens. HLA-B27 
has been extensively investigated for structural variations and functional roles, because 
of its strong association with ankylosing spondylitis and other spondyloarthropathies 
(Bowness et al., 1999).  
 
1.4.1 Polymorphism and evolution of HLA-B27 
There are 28 HLA-B27 alleles that have been identified by cellular, serological and 
biochemical techniques and encode 24 products (proteins) – HLA-B*2701 to HLA-
B*2725 (Table 1.1). With the systematic application of molecular typing this number 
is likely to increase further. These alleles are also called subtypes of HLA-B27. All of 
the subtypes differ from each other only in several amino acid positions mostly 
resulting from changes in exon 2 and 3, which encode the α1 and α2 domains, 
respectively (Table 1.2).  
HLA-B*2705 is the most widespread B27 subtype around the world and is clearly 
associated with AS and related spondyloarthritis (SpA) around the world, except 
among the west African population of Senegal and Gambia (Brown et al., 1997; 
Wordsworth et al., 1998). The sequence variation of the B27 subtypes and their pattern 
of distribution among the world population suggest that B*2705 might be the ancestral 
subtype from which others have evolved (Alvarez et al., 2000; Khan, 2000a) (Fig 1.6), 
so this subtype is listed first in table 2. Other subtypes can be related to it by the 
genetic mechanisms of reciprocal recombination, point mutation, and gene conversion 
(Mason et al., 1998; Alvarez et al., 2000; Marti et al., 2000). B*2705 is further 
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subdivided into B*27052, B*27053, B*27054, B*27055 and B*27056 by single silent 
nucleotide substitutions.  
B*2701 differs from B*2705 at positions 74, 77 and 81 in the C/F pocket. This 
subtype differs from most of the other in that its binding preference at P2 of the bound 
peptide is not restricted to arginine, it can also bind many peptides with glutamine at 

































B*2702 subtype differs from B*2705 by three amino acid changes, D77N, T80I and 
L81A (Vega et al., 1985; Seemann et al., 1986), which are located in the C/F pocket. 
B*2703 and B*2717 differ from B*2705 by a single amino acid substitution: tyrosine 
at position 59 is substituted by histidine in case of B*2703, and by phenylalanine in 
case of B*2717. B*2704, which seems to have evolved from B*2705 by three genetic 
events introducing single amino acid changes at position 77, 152 and 211, is a 
predominant subtype in Orientals. It has been suggested to be the progenitor from 
which B*2706 (Rojo et al., 1987) and other rare Asian subtypes have arisen (Figure 
1.7) (Ramos et al., 2002a).  
B*2706 has two changes relative to B*2704 at position 114 (His to Asp) and 116 (Asp 
to Tyr) involving charge alterations in the C/F pocket. B*2721 differs from B*2706 by 
only one amino acid substitution at residue 97. B*2707 allele differs from the B*2705 
by five amino acid substitutions related to the E-F pockets. B*2711 differs from 
B*2707 by a single amino acid substitution at position 77.  
It is of interest that B*2708, and a related subtype B*2712 are serologically quite 
distinct from other members of the B27 family. B*2708 and B*2712, along with 
another subtype B*2718, are unique among the B27 subtypes in having a Bw6 
supertypic epitope because of the Ser77, Asn80, Arg82, and Gly83 motif (Hildebrand 
et al., 1994; Armas et al., 1999). In contrast, all the other subtypes of B27 carry the 
Bw4 epitope. B*2709 differs from B*2705 only by an Asp to His substitution at 
position 116. This change is located in the C/F pocket and affects the C-terminal 
residue preference. B*2710 differs from B*2705 by a single substitution at position 
152. B*2713 is identical to B*2705 except for a single base change (from C to A) in 
the coding sequence of exon 1, which encode the leader or signal peptide (Seurynck et 
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al., 1998). Therefore, the structure of the expressed B*2713 molecule is identical to 
B*2705. 
B*2712, B*2716, B*2718 and B*2723 all share Thr/Asn/Thr at residues 69/70/71, 




















































Figure 1.7. Proposed evolutionary relationship among HLA-B27 subtypes. In this 
model, α3 and intron polymorphism were not taken into account, because sequence of 
these regions are not available for many subtypes. Relative to B*2704/B*2706, the 
precise evolutionary relationship among B*2708/B*27012/B*2716 are unclear 
(Ramos et al., 2002a).  
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1.4.2 Prevalence of HLA-B27 in world populations 
HLA-B27 is a serologic specificity that encompasses an increasing number of alleles, 
which have a varied racial/ethnic prevalence in the world (Alvarez et al., 2000; Khan, 
2000b; Ball et al., 2001). There is a striking correlation between the structural features 
of HLA-B27 subtypes and the ethnic distribution of these subtypes. 
HLA-B*2705 is a subtype present in nearly all populations throughout the world, but 
its prevalence varies among different populations. The predominant subtypes in Euro-
Caucasoid populations is B*2705, present in approximately 90% of the B27 positive 
normal individuals or patients with AS and related spondyloarthropathies (Gonzalez et 
al., 1994; Khan, 1995; Feltkamp et al., 1996; Muhammad, 1996). B*2705 is virtually 
the only subtype observed among the native populations of eastern Siberia and North 
America (Siberian Chukchis and Eskimos, Alaskan Eskimos, Inuits and North 
American India tribes) (Khan, 1995&1998).  
HLA-B*2701 is a very rare subtype observed in Caucasian, Asian, Mestizo and 
African American populations, and SpA has only been reported in a kindred (Taurog, 
1998). HLA-B*2702 is present in 4 to 10% of the B27-positive individuals of northern 
European extraction (Khan, 1995&1996). Its prevalence among B27 positive 
individuals increases in southern Europe to 20% in Spain, and up to 55% among 
Semitic (Arabs and Jews) B27 positive populations (Khan, 1995; Fraile et al., 1998; 
Lopez-Larrea et al., 1998).  
B*2705 (65%) and B*2703 (35%) are the predominant subtypes in west Africa 
(Brown et al., 1997; Wordsworth et al., 1998). The predominant subtype among 
African American is B*2705, whereas B*2703 is rare; very few AS patients with 
B*2703 have been observed (Khan, 1998). B*2704 is the predominant subtype in Asia 
among the Chinese and Japanese and has been suggested to be the progenitor from 
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which B*2706 and other rare Asian subtypes have arisen, such as B*2711, B*2715 
and B*2720 (Ball and Khan, 2001). B*2704 and B*2706 are equally prevalent in 
Thailand whereas B*2706 is predominant subtype in Indonesia (Gonzalez-Roces et al., 
1997). HLA-B*2707 is a relatively rare subtype in India and Europe (Khan, 1996). 
B*2705 (51%) is more common than B*2704 (40%) in northern India (Reveille et al., 
2001). HLA-B*2708 is a rare European subtype that has now been observed in 
association with AS in a large family from the Azores (Armas, 1999). HLA-B*2709 is 
primarily observed in Sardinians and continental Italian populations (D'Amato, 1995). 
B*2710 is a very rare subtype that was observed only in Caucasian American family 
with SpA (Taurog, 1998). The remaining B27 subtypes are extremely rare and have 
not yet been studies for any disease association.  
 
1.4.3 HLA-B27 structure  
It is known that the principle function of HLA molecules is to bind and present 
antigenic peptides to T cells (Townsend et al., 1986). The most important function of 
HLA class I molecules is to present peptides to CD8+ cytotoxic T lymphocytes (CTLs).  
Because of the pronounced disease association, HLA-B27 was among the first MHC 
molecules whose structures were elucidated (Madden et al., 1991; Madden et al., 
1992). Much is now known of the molecular structure, peptide binding specificity and 
cell biology of HLA-B27.  
The overall structure of B27 was found to be very similar to other HLA class I 
molecules (Figure 1.4) (Bjorkman et al., 1987a; Garrett et al., 1989), with peptide 
fragment of other proteins cradled in a deep cleft in the top of the molecule (Figure 
1.8). HLA-B27 has common structure with other HLA class I molecules (Fig 1.4). 
Peptide occupies a groove formed by the α1 and α2 domain at the membrane-distal 
surface of the class I molecule. The peptide-binding site is composed of parallel α 
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helices positioned over a sheet of eight β-pleated strands. The membrane-proximal α3 
domain pairs with β2m to form a pedestal-like structure that supports the peptide-






















Figure 1.8. Top view of HLA-B*2705 molecule binding peptide within 
the cleft. The peptide is bound in an elongated conformation with both ends 
tightly bound at either end of the cleft (Adnane, 2001). 
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The most distinctive structural feature of HLA-B27 is its deep B pocket. This pocket 
comprises a unique combination of residues: His9, Thr24, Glu45 and Cys67, which 
confers the HLA-B27 B pocket with a strong specificity for an arginine side chain at 
the second position of bound peptide. The side chains of peptide residues P3, P7 and 
the C-terminus are also restricted and are accommodated in the D, E and C/F pockets, 
respectively. This strict selection of peptides was confirmed by amino acid analysis of 
self-peptide eluted from HLA-B27 (Jardetzky et al., 1991; Rotzschke et al., 1994) and 
binding studies using synthetic peptide (Galocha et al., 1996).  
The crystal structure of HLA-B27 shows that short peptide adopts a largely extended 
conformation within a peptide binding groove. P2, P3, P7 and P9 face inward to 
contact the HLA-B27 molecule, and the terminal carboxyl and amino groups fit into 
the ends of the groove; P4 and P8 point up to towards the solvent; P5 and P6 could be 
simultaneously in contact with the HLA-B27 molecule and accessible to direct contact 
by a T-cell receptor.   
 
1.4.4 HLA-B27 and disease 
HLA-B27 molecules show a remarkable association with ankylosing spondylitis (AS) 
(Brewerton et al., 1973a), reactive arthritis (ReA) (Brewerton et al., 1973b) and other 
spondyloarthropathies (SpA) (McMichael et al., 2002), but the mechanism of 
pathogenesis remains a mystery. A recent study showed that 94% of AS patients 
express HLA-B27 compared with only 9.4% of controls, giving an odds ratio of 171, 
with a 95% confidence interval of 135-218 (Brown et al., 1996).  
 
1.4.4.1 Association of HLA-B27 subtypes with spondyloarthropathy 
B27 have strong association with spondyloarthropathies (SpA), but it is very 
interesting that different B27 subtypes have differential association with AS and other 
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SpA. Since structural polymorphism may influence the peptide binding specificity and 
other biochemical and functional features of HLA-B27, differential association of 
HLA-B27 subtypes with AS may provide significant insight into the mechanism of this 
association.  
Case control studies have shown that B*2705, B*2702, B*2704 and B*2707 are 
associated with AS (Gonzalez-Roces et al., 1997). The association of B*2703 with AS 
is still unclear. B*2703 is restricted to Negro population of West Africa and to Afro-
Americans. Previous study proposed that HLA-B*2703 may be negatively associated 
with ankylosing spondylitis, thus accounting in part for the rarity of this disease in 
black populations (Hill et al., 1991). Another case control study carried out in the Fula 
group of Gambia showed that neither B*2703 nor B*2705 were associated with AS, 
suggesting that this population might be protected by unknown genetic factors (Brown 
et al., 1997). The report of three B*2703 positive AS patients from Senegal suggests 
that this allele maybe positively associated to AS (Gonzalez-Roces et al., 1997), so 
more studies need to carry out to investigate the disease association of B*2703.  
B*2706 and B*2709 have been reported to be weakly or not associated with AS, 
although they are ethnically and geographically restricted to Thai and Sardinians, 
respectively. One case-control study in the Thai population initially reported the 
negative association of B*2706 with AS. In this series B*2704 was frequent both 
among controls (47%) and patients (91%). While B*2706 allele was found to be over-
represented in this population but absent in AS patients, indicating that B*2706 is not 
associated with AS in Thais (Lopez-Larrea et al., 1995). This result was confirmed 
upon retyping this series, plus a few additional individuals, to take into account newly 
described subtypes (Garcia-Fernandez et al., 2001). Subsequent studies carried out in 
Singapore (Ren et al., 1997), Indonesia (Nasution et al., 1997; Mardjuadi et al., 1999), 
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and Taiwan (Wei et al., 1998) have confirmed that B*2706 is not associated with AS. 
However, two B*2706 patient were observed in mainland China (Gonzalez-Roces et 
al., 1997), where this subtype is very rare. So the lack of B*2706 association with AS 
found in Asian populations is not absolute. The positive and negative association could 
be interpreted in the context of the geographical differences of the environmental 
factors involved in the disease. The lack of B*2706 association with AS could be 
geographically restricted to Southeast Asian populations and show a low relative risk 
in the China region. Moreover, B*2706 is not capable of preventing development of 
SpA in an individual who has co-inherited a disease susceptible HLA-B27 subtype 
(Sudarsono et al., 1999).  
The B*2709 subtype occurs with high frequency among Italians, particularly on the 
island of Sardinia. One case-control study carried out in island population of Sardinia 
suggested that B*2709 have a negative association with AS in this population 
(D'Amato et al., 1995). No B*2709 AS patients have been found in continental Italy, 
however at least four patients with undifferentiated SpA have been reported. The first 
patient with undifferentiated SpA was from continental Italy and had oligoarthritis and 
sacroiliitis (Marchionni et al., 1999). The second one was from southern continental 
Italy and showed peripheral arthritis and enthesitis, but no axial involvement (Olivieri 
et al., 2000). Subsequently the same group reported two additional B*2709 SpA 
patients in the same region, and the two patients also had undifferentiated SpA without 
axial pathology (Olivieri et al., 2002). Recently the HLA-B27 subtyping has been 
extended to 70 AS patients from Sardinia and 70 from continental Italy and none of 
them was B*2709 positive (Mathieu et al., 2003). All of the data strongly suggest that 
B*2709 is weakly or not associated with AS, although it may confer susceptibility to 
other SpA.  
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The remaining HLA-B27 subtypes are extremely rare, and have not yet been studied 
for any disease association.  
 
1.4.4.2 Hypotheses of HLA-B27 with spondyloarthropathy 
In spite of intense research and advanced knowledge of the biochemistry and biology 
of HLA molecules, the mechanism between the HLA-B27 and spondylarthropathy 
remains obscure. Substantial evidences have shown that HLA-B27 molecules are 
directly involved in disease pathogenesis (Lopez de Castro, 1994& 1995). First, in all 
population studies the susceptibility to these disease correlates only with HLA-B27 
antigens. The other is that HLA-B27 transgenic rats and mice of the appropriate 
genetic background develop a disease resembling human spondyloarthritis (Hammer et 
al., 1990; Khare et al., 1995).  
Most current ideas concerning the pathogenetic role of HLA-B27 fall into three 
categories. The first one is the arthritogenic peptide hypothesis, which assumes that a 
self-peptide presented by HLA-B27 would be the target of autoimmune CTLs 
activated by external antigen, such as bacteria (Benjamin and Parham, 1990). The 
second one is the activation of unusual T cell responses and inflammation following 
non-classical T-cell recognition of β2-microglobulin (β2m)-free HLA-B27 heavy chain 
(Allen et al., 1999; Edwards et al., 2000). The third one is HLA-B27-associated 
inflammatory responses would be the result of endoplasmic reticulum (ER) stress  
responses triggered by accumulation of misfolded HLA-B27 heavy chain (Mear et al., 
1999; Colbert, 2000).  
Arthritogenic peptide hypothesis is the most favored model in recent years and 
assumed that cross-reaction of some activated CTL with the self-peptide would lead to 
autoimmune tissue damage and inflammation (Benjamin and Parham, 1990). There is 
much indirect evidence supporting this hypothesis. First is the finding of HLA-B27-
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restricted CD8+ CTL in the synovial fluid of ReA patients (Hermann et al., 1993; 
Ugrinovic et al., 1997). Second is the finding of HLA-B27-restricted CTL directed 
against self-epitopes in patients with ReA and AS (Hermann et al., 1993; Fiorillo et al., 
2000). Third is the influence of the B27-bound peptide repertoire on development of 
arthritis in transgenic rats (Zhou et al., 1998). In HLA-B27 transgenic rats, alteration 
of the endogenous HLA-B27-bound peptide repertoire by over-expression of a 
minigene-encoded viral peptide with high affinity for HLA-B27 resulted in significant 
reduction in the prevalence of arthritis. Lastly, the differential association of HLA-B27 
subtypes to AS is also strongly suggestive of peptide involvement in the pathogenesis 
of this disease, as HLA-B27 polymorphism significantly affects peptide specificity and 
CTL recognition.   
 
1.4.4.3 Peptide interaction with HLA-B27 subtypes 
Due to the strong association of HLA-B27 with ankylosing spondylitis (AS), the fact 
that some HLA-B27 subtypes are weakly or not associated to disease, and the possible 
pathogenetic role of natural HLA-B27 ligands (Benjamin et al., 1990; Scofield et al., 
1995; Fiorillo et al., 2000), the antigenic and peptide-binding properties of HLA-B27 
have special interest. The differential association of HLA-B27 subtypes with AS and 
the arthritogenic hypothesis suggest that disease-linked subtypes could differ from the 
other subtypes by their ability to bind bacterial or self-derived arthritogenic peptides. 
This could be reflected in their peptide binding specificity.  
 
1.4.4.3.1 Peptide motif selected by HLA-B27 subtypes 
Basic information on peptide motif selected by HLA-B27 molecules derives from 
amino acid sequencing of pooled and individual naturally bound peptides (Jardetzky et 
al., 1991; Rotzschke et al., 1994; Garcia et al., 1997b; Tieng et al., 1997) and from 
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crystallographic studies (Madden et al., 1991, 1992). Recently rather straightforward 
picture about the peptide binding specificity has been modified to some extent by 
studies in which mass spectrometry was used for systematic screening and more 
extensive sequencing of HLA-B27-bound peptide repertoires. Much of the effect in 
identifying the motifs of the natural peptides focused on the subtypes which 
relationship to disease has been established from population analyses: 
B*2705/02/03/04/06/07/09. All of these studies identified that HLA-B27 molecules 
bind prevalently nonamer peptides through primary anchors, positions 2 and position 9 
(Jardetzky et al., 1991; Fruci et al., 1994). The affinity of HLA-B27 molecule with 
peptide is further enhanced by the interaction between the peptide residues and 
secondary anchors at position 3 and position 7 (Lamas et al., 1999). The six pockets 
positions are similar to other HLA class I molecules shown in Figure 1.5. The amino 
acid residues involved in the formation of B27 pockets are shown in Table 1.3 and the 
anchor residues P1, P2, P3, P7 and P9 accommodated by pocket A-F are also shown in 
Table 1.3.  
Arg at P2 is the main anchor motif for all HLA-B27 subtypes, and the overwhelming 
majority of natural HLA-B27 ligands have this residue. Recent studies found natural 
ligands with Gln2 in the B*2705-bound peptide pool (Alvarez et al., 2001). Natural 
ligands with Gln2 are frequent in B*2701 (Garcia et al., 1997), because of a long-
range effect of Asp74Tyr change in this subtype on B pocket interactions, which is 
mediated by Lys70 (Krebs et al., 1999). A natural ligand with Lys2 has also been 
reported in B*2705 (Fiorillo et al., 1997). For position 1, there is a preferential 
acceptance of basic or aromatic residue (Lamas et al., 1999), and for P3 and P7, large 
or hydrophobic amino acids have more tolerance in these position than other residue 









Pocket A - P1 Pocket B - P2 
 
Pocket C - P9
 5 9 59 63 66 99 163 167  9 24 34 45 63 66 67 70 99  9 70 73 74 97
B*2705 M H Y E I Y E W  H T E E E I C K Y  H K T D N
B*2702 - - - - - - - -  - - - - - - - - -  - - - - -
B*2703 - - H - - - - -  - - - - - - - - -  - - - - -
B*2704 - - - - - - - -  - - - - - - - - -  - - - - -
B*2706 - - - - - - - -  - - - - - - - - -  - - - - -
B*2707 - - - - - - - -  - - - - - - - - -  - - - - S
B*2709 - - - - - - - -  - - - - - - - - -  - - - - -
      
 
Pocket D - P3 
  
Pocket E - P7 
  
Pocket F - P9 
 
 99 113 114 155 159 160   97 114 147 152 156   77 80 81 82 83 84 116 143  
B*2705 Y Y H Q L Y   N H W V L   D T L L R Y D T  
B*2702 - - - - - -   - - - - -   N I A - - - - -  
B*2703 - - - - - -   - - - - -   - - - - - - - -  
B*2704 - - - - - -   - - - E -   S - - - - - - -  
B*2706 - - D - - -   - D - E -   S - - - - - Y -  
B*2707 - H N - - -   S N - - -   - - - - - - Y -  
B*2709 - - - - - -   - - - - -   - - - - - - H -  
 
Table 1.3. Polymorphic amino acid residues involved in formation of B27 pockets. 
Residues from seven HLA-B27 alleles involved in each pocket are identified by their 
position number. The position of peptide residue which fit into each pocket is also 
indicated. The letter in the table ins the one-letter symbol of amino acid (Lopez-Larrea 











The amino acid representation at the primary anchor position P9 is more flexible. 
Initial studies have indicated that all B27 subtypes bind peptides with Arg at position 2 
but have significant differences in their specificity for C-terminal residues. C-terminal 
residue variances were more variable, being basic, aliphatic or aromatic in B*2705 and 
B*2703 (Jardetzky et al., 1991; Rotzschke et al., 1994; Boisgerault et al., 1996; 
Fiorillo et al., 1997; Griffin et al., 1997). B*2702 and B*2704 appeared to be 
restricted to C-terminal aliphatic or aromatic, but not basic residue (Rotzschke et al., 
1994; Garcia et al., 1997b). B*2706, B*2707 and B*2709 were even more restricted in 
the C-terminal residue specificity as they bound only peptide with aliphatic or 
aromatic residue, but not Tyr at this position (Fiorillo et al., 1997; Garcia et al., 1997b; 
Tieng et al., 1997). Previous studies have suggested that putative arthritogenic peptide 
was likely to have Arg 2 and lack a basic C-terminal residue, since this motif was not 
found among natural ligands from the disease associated B*2702, B*2704 and B*2707 
subtype. In addition, neither B*2706 nor B*2709 showed a C-terminal Tyr motif 
suggested that arthritogenic peptide might have C-terminal Tyr. But this was 
challenged by absence of this motif among natural ligand of B*2707 (Tieng et al., 
1997).  
Recently some novel findings arose from the studies in which mass spectrometry was 
used. Three natural peptides with C-terminal Arg have been found in B*2704 peptide 
repertoires (Sesma et al., 2002). Two peptides with C-terminal Arg and Tyr were 
revealed in B*2709-bound peptide pool, although the amount of both peptides were 
much more abundant in disease-associated subtype B*2705 than in B*2709 (Ramos et 
al., 2002). These peptides seem to be a minor, but perhaps immunologically significant, 




1.4.4.3.2 Overlap among subtype-bound peptide repertoires 
Large sharing of natural ligands have been found in structurally close HLA-B27 
subtypes by systematic pairwise comparisons of peptide repertoires. B*2705- and 
B*2702-bound peptide repertoires overlap with each other by 73% and 81%, 
respectively (Marti et al., 2001). B*2704- and B*2706-bound peptide repertoires 
overlap by 88% and 90%, respectively. Peptide differentially bound to these two 
subtypes showed further differences at secondary anchor positions, indicating that the 
two amino acid changes between B*2704 and B*2706 have a rather complex 
modulatory effect on their peptide repertoires (Sesma et al., 2002). B*2705- and 
B*2709-bound peptides overlap by 79% and 88%, respectively (Ramos et al., 2002). 
Subtype polymorphism modulates the amount of particular peptides, so that a number 
of shared ligands were much more abundant in one subtype than in the counterpart 
with which it was compared.  
Subtypes with more restricted C-terminal peptide motifs, such as B*2702 and B*2709 
relative to B*2705, or B*2706 relative to B*2704, do not have significantly smaller 
peptide repertoires. As expected, peptides differentially bound to B*2705 or B*2704 
corresponded to those with C-terminal motifs not accepted by the subtypes with which 
they were compared. In contrast, multiple B*2706 or B*2709 ligands not found in 
B*2704 or B*2705, respectively, had C-terminal aliphatic motifs acceptable for these 
subtypes (Ramos et al., 2002; Sesma et al., 2002). The same applies to the relationship 
between B*2702- and B*2705-bound peptide peptides (Marti et al., 2001).  
 
1.4.4.3.3 Antigenic features of shared ligands in the context of different subtypes 
Another complexity in defining the nature of putative arthritogenic peptide arises from 
the issue that the antigenic features of a given peptide may change depending on the 
subtype to which it is bound. Thus, it is conceivable that a shared ligand of multiple 
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HLA-B27 subtypes might be relevant to arthritogenesis only when presented by some 
of them. Subtype polymorphism may have two effects on peptide presentation. First is 
a given ligand may bind different subtypes with different affinity and stability, and the 
other is the ligand’s conformation may be altered when bind to different subtypes. The 
first effect may influence the immunogenicity of the peptide, whereas the second effect 
may alter its antigenic features. In the context of the arthritogenic peptide hypothesis, 
in which autoreactive CTL are assumed to be triggered by external antigens, the 
antigenic properties of the self-antigen, rather than its immunogenicity, are particularly 
relevant.  
X-ray diffraction studies provide molecular detail of the interactions among peptides, 
MHC molecules and T-cell receptors (TCR). However, they may not allow us to derive 
a general rule for predicting antigenic similarity of a given peptide in multiple MHC 
contexts, because a general rule may not exist. Indeed, small conformational changes 
in the peptide epitope may sometimes abrogate cross-reactivity or, in other cases, favor 
it. The crystal structures of B*2705 and B*2709 in complex with a same peptide have 
been established at high resolution. Aside from significant differences in peptide-HLA 
interactions, the conformation of the peptide on both subtypes was very similar, but 
showed small differences in the central region (Hulsmeyer et al., 2002). These 
differences might be distinguished by particular TCR, but other TCR might still 
crossreact. Indeed, TCR are capable to distinguish among subtle conformational 
differences, but they can also adapt their conformation to changes in the peptide 
epitope. The antigenic properties of peptides bound to different subtypes must be 
tested with CTL.  
Some peptide-specific HLA-B27-restricted CTL clones recognize same peptide in the 
context of different subtypes, but others do not (Fiorillo et al., 1998; Lamas et al., 
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1998). Thus, although peptide presentation is altered upon binding to different 
subtypes, a certain level of crossreaction is usually maintained at the clonal level. 
Alloreactive CTL has been used to analyze the extent to which shared ligands can be 
recognized by a same T-cell clone in the context of different subtypes. Anti-B*2705 
CTL exhibit various degrees of crossreaction with B*2701-B*2706, suggesting that a 
number of shared ligands are recognized in the context of different subtypes by 
individual CTL clones (Lopez D et al., 1994). Anti-B*2702 CTL also show significant 
crossreaction with B*2705, in agree with the large peptide sharing between these two 
subtypes (Marti et al., 2001). Similar CTL crossreaction have been observed between 
related subtype pairs differentially associated with AS: B*2704/B*2706 (Sesma et al., 
2002) and B*2705/B*2709 (Garcia-Peydro et al., 1999; Ramos et al., 2002). Although 
alloreactive CTL are unrelated to spondyloarthropathies, these studies showed that 
many shared ligands between subtypes differentially associated with AS largely 
conserve their antigenic properties in both contexts. Thus, differential subtype 
association with AS is probably the result of differential binding of particular peptides, 
rather than of differential antigenicity of shared ligands.  
 
1.4.4.4 Molecular mimicry of self derived ligands with viral and bacterial peptides 
The arthritogenic peptide hypothesis predicts that some self-peptides presented by 
HLA-B27 may show molecular mimicry with bacterial antigens. This hypothesis 
would be supported by the identification of self-peptides with homology to proteins 
from microorganisms potentially related to arthritogenesis, specially if binding of these 
ligands to subtypes correlates with association with AS. Recently a self-peptide with 
high homology to an HLA-B27-restricted Epstein-Barr virus-derived epitope was 
found (Fiorillo et al., 2000). AS patients showed higher frequency of T cells reactive 
against this self-peptide than healthy individuals. Another finding that HLA-B27 
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contains a region in the α2 domain of its heavy chain with homology to proteins from 
gram-negative bacteria suggested that a putative arthritogenic peptide might be an 
HLA-B27 derived one, presented as natural ligand by HLA-B27 itself (Scofield et al., 
1995). A peptide derived from this region, spanning residues 169-181, was identified 
as a natural ligand of B*2705 and B*2704, and was absent or in minimal amounts in 
B*2706 and B*2709. Thus, its presence in subtype-bound peptide pools correlated, 
albeit incompletely, with association with AS (Alvarez et al., 2001b). A new 
dodecamer peptide from the intracytoplasmic tail of HLA-B27 and other HLA-B 
molecules was identified recently (Ramos et al., 2002c). This peptide is a natural 
ligand of at least three AS-associated subtypes (B*2702, B*2704 and B*2705), but 
was not detected in the peptide pools from B*2706 or B*2709. This peptide was 
strongly homologous to proteins from Chlamydia and other arthritogenic bacteria, thus 
providing a striking example of a self-peptide showing molecular mimicry with 
bacteria proteins and subtype distribution that closely correlates with association with 
AS. 
 
1.5 Objectives of this study 
As shown in the previous sections, HLA-B27 molecules have strong association with 
spondylarthropathries, but its disease mechanism remains unknown. The arthritogenic 
peptide hypothesis suggests that HLA-B27 disease-linked subtypes could differ from 
the other subtypes by their ability to bind bacterial or self-derived arthritogenic 
peptides. This could be reflected in their peptide binding specificity. Most of the 
known data regarding the HLA-B27 peptide specificity showed that Arg at P2 is a 
rather rigidly maintained feature, in contrast, C-terminal residue was more variable. 
HLA-B27 polymorphism affects mainly the C/F cavity of the peptide binding site 
which accommodate peptide C-terminal residue, but the preference of peptide C-
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terminal residue for the differential disease associated HLA-B27 subtype has not been 
clearly defined. So this study aims to study the peptide binding specificity at position 9. 
Most of the data concerning the peptide specificity come from pool sequencing or 
mass spectrometry analysis of natural peptide repertoire or cellular binding assay, but 
this study employed the refolding method which reconstitutes the HLA-B27/peptide 
complex using the recombinant protein in vitro. 
 
The aims of this study include the following aspects: 
1: To clone and express HLA-B*2702/03/04/05/06/07/09 heavy chain and light chain 
(β2-microglobulin) protein.  
2: To reconstitute the HLA-B27/peptide complex in vitro using the recombinant HLA-
B27 heavy chain, light chain and peptide.  
3: To explore the effects of variability at the peptide C-terminal anchor residue on its 
binding to differential disease associated HLA-B27 subtypes. 
4: To explore the linkage between the disease association and peptide binding 
specificity. 












































2.1 Media, Buffers and Solutions 
 
The media used in this study are listed in Appendix 1. All reagents, buffers and 
solutions are listed in Appendix 2. 
 
2.2 Bacterial strains, plasmids and culture conditions 
 
2.2.1 Bacterial strains and plasmids 
The bacterial strains and plasmids together with their relevant characteristic are listed 
in Table 2.1 and 2.2. The maps of plasmid vectors are listed in Appendix 4. 
 
2.2.2 Culture conditions 
Escherichia coli (E. coli) strain BL21 (DE3) was used as a host for cloning and protein 
expression throughout this study. Strain XL1-Blue was used as a host for site-directed 
mutagenesis. The E. coli strain BL21(DE3) was cultured either in Luria-Bertani (LB) 
broth or maintained on LB agar plates at 37°C. Strain XL1-Blue was cultured in NZY+ 
Broth. Media was supplemented with 30µg/ml kanamycin when E. coli strains 
containing recombinant plasmids were cultured. 
 
2.2.3 Storage of bacterial strain 
The E. coli strains with and without the recombinant plasmid were kept as glycerol 
stock at -80°C for longer use. A single E. coli colony with or without plasmid was 
inoculated into 3ml LB with 30µg/ml kanamycin or LB broth and grown at 37°C 
overnight with shaking at 220rpm. Zero point five milliliter culture was mixed with 
0.5ml glycerol (LB with 40% glycerol) and transfer to cryovial tubes and kept at -80°C.  
 




Table 2.1. Table of bacterial strains used in this study 
 
Bacteria strains Relevant characteristics Source 
Escherichia coli   
BL21 (DE3) F- ompT hsdSB (rB-mB-) gal dcm (DE3) Invitrogen 
INV110 F' tra, ∆36proAB, lacIqZ∆M15/rpsL, 
StrR, thr, leu, endA, thi-1, lacY, galK, 





TOP10 F-, mcrA, ∆(mrr-hsdRMS-mcrBC), 
ф80lacZ∆M15, ∆lacX74, deoR, recA1, 
araD139, ∆(ara-leu)7697, galU, galK, 
rpsL(StrR), endA1, nupG 
Invitrogen 
XL1- Blue recA1, endA1, gyrA96, thi-1, λ-, lac-, 
hsdR17(rK-,mK+), supE44, relA1, 
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Table 2.2. Table of plasmids used in this study 
Plasmids Relevant characteristics Sources 










2.3 Expression cloning 
 
2.3.1 Preparation of competent cells 
E. coli strain BL21(DE3) (Invitrogen, Carlsbad, CA) was prepared for chemical 
transformation. Stock cells were streaked onto Luria Bertani (LB) agar plate and 
incubated overnight at 37°C. A single colony was inoculated into 10ml LB medium 
and grown at 37°C overnight with vigorous shaking at 220 rpm. Five milliliter of the 
overnight culture was inoculated into 500ml LB medium and the cells were grown at 
37°C with shaking at 220rpm until OD600 reach 0.6. The cells were then harvested by 
centrifugation at 1,800 × g for 15 min at 4°C. The cells were resuspended in 100ml of 
ice-cold TfB I buffer (Appendix II) and collected by centrifugation at 1,400 × g for 8 
min at 4°C. After the supernatant was discarded, the cells were gently resuspended in 
20ml of ice-cold TfB II buffer (Appendix II) then aliquoted into eppendorf tubes, 
rapidly frozen in liquid nitrogen and stored at -80°C. 
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2.3.2 Preparation of insert DNA fragment 
 
2.3.2.1 Total RNA extraction 
High Pure RNA Isolation kit (Boehringer Mannheim, Indianapolis, IN) was used in the 
total RNA extraction from EBV-transformed B-Lymphoblastoid Cell line. 1x106 cells 
were resuspended in 200µl PBS and the RNA was isolated as recommended by the 
manufacturers using the reagents supplied in the kit. RNA was resuspended in the 50µl 
elution buffer and stored at -80°C. The quantity of total extracted RNA was calculated 
by multiplying the spectrophotometric reading (λ=260 nm) by 40µg/ml and by dilution 
factor.  
 
2.3.2.2 Reverse transcription – polymerase chain reaction (RT-PCR) 
 
QIAGEN OneStep RT-PCR kit (Qiagen Gmbh, Hilden, Germany) was used in the RT-
PCR for cDNA synthesis. The RT-PCR reaction was performed in a total volume of 
50µl consisting of 10µl 5x buffer, 2µl dNTP (400µM of each at final concentration), 
2µl Enzyme mix, 0.5µl RNase inhibitor (supplied by the kit), the sense and anti-sense 
RT-PCR primers (0.6µM of each at final concentration), 2 µg template RNA, 0.25µl 
pfu DNA polymerase (Stratagene, La Jolla, CA) and sterile double-distilled water. The 
reaction was carried out in DNA thermal cycler (Applied Biosystems, Foster City, CA) 
with the thermal cycler program of 50°C for 30 min, 95°C for 15 min, 35 cycles with 
each consisting of 94°C for 30 sec, 68°C for 1 min and 72°C for 1 min, followed by 
final 72°C for 10 min. Negative controls were performed in the absence of RNA 
template. The amplified products were separated on 1% agarose gel and visualized 
under UV transillumilator.  
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2.3.2.3 DNA extraction from agarose gel 
The QIAGEN quick Gel Extraction kit (Qiagen) was used in the extraction of the DNA 
from the agarose gel. After the DNA was subjected to gel electrophoresis, the DNA 
fragment with expected size was cut out and weighed. Gel extraction was performed 
using the reagents supplied in the kit according to the manufacturer’s instruction. This 
kit is designed to extract and purify DNA of 70bp to 10kb from standard or low-melt 
gels in TAE or TBE buffer. 
 
2.3.3 Cloning of insert DNA fragment into TA vector 
TA cloning involves the ligation of RT-PCR generated inset with an A overhang to a 
vector with a T overhang. This ensures that subsequent digestion of the engineered 
restriction sites at both ends of the insert using would be more efficient. The TOPO TA 
cloning kit (Invitrogen) was used in the cloning of insert DNA fragment into TA 
vector. Two microliter of RT-PCR product was ligated to pCR2.1-TOPO (supplied by 
the kit) in a 6µl reaction according to manufacturer’s instruction. In addition to 2µl 
DNA fragment, the 6 µl reaction contained 1µl salt solution, 1µl TOPO vector and 2µl 
sterile water. After being incubated at room temperature for 5 min, 2µl of the ligated 
product was transformed into One ShotTM TOP 10 cells (Invitrogen), recovered and 
grown onto LB agar supplemented with kanamycin and X-gal. The white colonies 
were picked for screening. 
 
2.3.4 Restriction digestion of inserts and plasmid vector 
HLA-B27 subtypes heavy chain genes were needed to be subcloned into the 
expression vector pET30-BirA for protein expression. Each of the plasmid DNA of the 
TA clones pCR2.1-TOPO-B*2702/04/05/06 was digested in separate reaction. The 
plasmid DNA was extracted from 10ml overnight culture. Fifty microliter restriction 
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digestion reaction consisted of 25µl of plasmid DNA, 2.5µl Nhe I, 2.5µl BamH I 
(added 4 hr later after Nhe I digestion), 5µl of 10× multiple buffer, 0.5µl BSA 
(Promega U.S., Madison, WI) and sterile water. The reaction was carried out by 6 hr 
incubation at 37°C. Plasmid expression vector pET30-BirA was digested similarly as 
TA clones. One hundred microliter reaction contained 79µl of vector DNA, 5µl Nhe I, 
5µl of BamH I (added 4 hr later after Nhe I digestion), 10µl 10× multiple buffer, 1µl 
BSA and sterile water with appropriate volume. The reaction was carried out by 8 hr 
incubation at 37°C. All the digestion products were separated on 0.8~1.0% agarose gel 
and viewed under UV transillumilator. The DNA fragment with expected size was cut 
out and purified using QIAquick Gel Extraction kit (Qiagen) according to the 
manufacturer’s instruction.  
 
2.3.5 DNA ligation 
Ligation reaction was usually carried out in triplicate in a 10µl of total volume 
containing 0.5µl T4 DNA ligase (New England Biolabs, Inc, Beverly, MA), 1x ligase 
buffer (New England Biolabs), 1µl 10x ATP (New England Biolabs) and appropriated 
amount of digested insert DNA fragment and vector. The amount of insert DNA 
fragment and vector is in the ratio of one to two with the amount of DNA 100ng, 
250ng and 500ng in each reaction. The mixture was incubated overnight at 16°C. The 
ligation product was used in transformation without further treatment. 
 
2.3.6 Transformation into bacterial hosts 
Chemical transformation was performed by a heat shock treatment at 42°C. The 
ligation product was added directly into 100µl of appropriate competent cells and 
mixed gently. The mixture was incubated on ice for 30 min and followed by a heat 
shock at 42°C for 30 seconds and then immediately cooled on ice for 2 min. The cells 
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were then mixed with 250µl SOC media and incubated at 37°C with shaking at 
220rpm for one hour. The cells were then plated on kanamycin LB agar plates and 
incubated at 37°C for 16 hours. 
 
2.3.7 Selection and screening of transformants for clones 
For the TA clones, 15 white colonies per set of experiment were picked for screening. 
Each colony was inoculated into 100µl LB medium supplemented with 30µg/ml 
kanamycin and grown at 37°C with shaking at 220rpm for 2 hours. Colony cultures 
were analyzed by PCR with the primer set T7F and M13R. Potential colonies having 
the PCR amplification product with the expected size were inoculated into 5ml 
kanamycin LB broth and grown overnight at 37°C with shaking at 220rpm. The 
plasmid DNA was extracted using the QIAGEN Spin miniprep kit (Qiagen) and was 
confirmed by DNA sequencing.  
For the pET30-BirA clones, up to 10 colonies were picked out in each transformation 
and subjected to PCR analysis with the primer set of T7F and T7R, followed by the 
confirmation of DNA sequencing.  
 
2.4 DNA analysis 
 
2.4.1 Agarose gel electrophoresis 
Electrophoresis of agarose gel was performed using the submerged horizontal gel 
system from BRL. One percentage and 0.8% gel were used for the analysis of DNA 
fragments in this study. Agarose was dissolved in 1× TBE buffer to an appropriate 
concentration. Ethidium Bromide Solution (Bio-Rad, Hercules, CA) was added to a 
concentration of 0.5ug/ml before the gel was poured onto a casting tray. DNA samples 
were mixed with a 0.1 volume of 10× loading buffer (Promega) and then loaded into 
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the wells of the gel. The 1kb DNA ladder (Promega) was used as the standard. 
Electrophoresis was carried out at a constant voltage of 120 V in 1× TBE buffer. The 
DNA samples were then visualized using an UV-transilluminator and photographed on 
a Polaroid MP4 camera. 
 
2.4.2 Determination of DNA concentration 
The quantity of the extracted DNA was determined by spectrophotometric quantitation. 
Seven microliter of DNA sample was diluted 10 fold to a total of 70µl for quantitation. 
The sample was read at 260nm and 280nm in GeneQuant pro RNA/DNA Calculator 
(Amersham Biosciences Europe GmbH, Freiburg, Germany). The DNA concentration 
was calculated by multiplying the absorbance reading at 260nm by 50µg/ml and by 
dilution factor 10. The purity of the DNA sample was determined by the ratio of 
absorbance reading at 260nm to 280nm with a desired ratio value of 1.7-1.9. 
 
2.4.3 DNA sequencing 
The ABI Prism Big DyeTm Terminator Cycle Sequencing Ready Reaction kit (Perkin 
Elmer Applied Biosystems Division, Foster City, CA) was used for DNA sequencing. 
The reaction mixture of 10µl consisted of 2µl of Big Dye Terminator, 1µl of 5× 
sequencing buffer, 250ng of palsmid DNA as the template, 1 µM of primer and sterile 
double-distilled water. The cycle sequencing reactions were performed in the DNA 
Thermal Cycler 2400 (Perkin Elmer Applied Biosystems). The cycling profile used 
was 25 cylcles of 96°C for 30 sec, 50°C for 15 sec and 60°C for 4 min. After reaction 
the extension products were needed to be purified for sequencing. Twenty five 
microliter of absolute ethanol and 1µl of 3M sodium acetate (PH4.6) were added to the 
reaction tube and the tube was put at -20°C for 20 min to precipitate the extension 
products. Spin the tube for 15 min at maximum speed at 4°C then the supernatant was 
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aspirated. Two hundred microliter of 70% ethanol was added to rinse the pellet and 
spin the tube for 5 min at maximum speed. Aspirate the supernatant and dry the tube at 
70°C for 10 min. Resuspend the sample with 15µl Template Suspension Buffer (ABI 
Prism) and heat the sample at 90°C for 2 min then transfer the sample to sequencing 
tube. The running of the gel and the automated analysis of the results were carried out 
using the ABI Prism 310 sequencer (Perkin Elmer Applied Biosystems).  
 
2.5 Plasmid extraction 
The QIAGEN Spin Miniprep kit (Qiagen) was used in the isolation of plasmid DNA 
from E. coli strains. A culture was prepared by inoculating an isolated E. coli colony 
into 5ml LB broth supplemented with the appropriate antibiotic and grown at 37°C 
with shaking at 220rpm overnight. The cells were harvested by centrifugation at 
4,000× g for 5 min at room temperature. Plasmid DNA was isolated as recommended 
by the manufacturer’s instruction using the reagents supplied in the kit. 
 
2.6 Polymerase chain reaction (PCR)  
The amplification of DNA fragment in polymerase chain reactions allowed for the 
determination of the presence or absence of specific gene, the determination of the size 
of the genes and amplification of a specific gene for subsequent DNA sequencing 
reactions. 
PCR reactions were performed in the DNA thermal Cycler 2400. A typical 20µl 
reaction included one unit of Taq DNA Polymerase (Roche, Basel, Switzerland), 2µl 
of 10x polymerase buffer (Roche), 0.2µM of dNTP, 0.5µM of each primer, 2µl of 
100µl E. coli colony culture (described in 2.3.7) or appropriate DNA sample and 
sterile water to make up the volume. Cycling profiles was set as follow: an initial 
denaturation of 94°C for 10 min, followed by 35 cycles of 94°C for 1 min, 58°C for 1 
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min and 72°C for 3 min, and a final extension of 72°C for 10 min. Negative controls 
were performed in the absence of DNA template. Fifteen microliter of the PCR 
product was analyzed by 1.0% agarose gel electrophoresis. All the primers used for 




Table 2.3. Primers used for the various PCR reactions in this study 
Name Sense Sequences (5’-3’) 
SolB27F Forward GGGGGATCCCACTCCATGAGGTATTTCC 
SolB27R Reverse GGGGCTAGCGGACTGGGAAGACGGCTC 
T7 F Forward TAATACGACTCACTATAGGG 
T7 R Reverse GTTATTGCTCAGCGGTGGC 
M13R Reverse CAGGAAACAGCTATGACC 
 
 
2.7 Site-directed mutagenesis 
B*2703, B*2707 and B*2709 heavy chain constructs were generated by in vitro 
mutagenesis from B*2705 heavy chain construct using the QuickChange Site-Directed 
Mutagenesis kit (Stratagene). This method requires the use of two complementary 
primers containing the desired mutations for the PCR reaction. All the primers used for 
mutagenesis for specific subtype were listed in Table 2.4. B*2703 and B*2709 differ 
from B*2705 by a single substitution, so only one step mutation reaction and one set of 
primers were required to obtain the desired plasmid construct. B*2707 differs from 
B*2705 by five amino acid substitutions and the substitutions span widely, so three 
steps have to be performed consecutively to obtain B*2707 plasmid from B*2705 
construct, and each primer set was designed for each step.  
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Briefly, pET30-BirA-B*2705 was transformed into INV110 competent cell 
(Invitrogen) to obtain dam methylated plasmid DNA template. Pfu Turbo DNA 
polymerase (provided by the kit) was used in the cycle amplification process to 
generate copies of plasmid carrying the desired mutated bases. A typical 50µl reaction 
included 5µl of 10× reaction buffer (provided by the kit), 10ng of DNA template, 
125ng of oligonucleotide primer (forward and reverse each), 1µl of dNTP mix 
(provided by the kit) and appropriate water to make up the volume. The cycle 
parameters used were an initial cycle of 95°C for 30 sec, followed by 18 cycles of 
95°C for 30 sec, 55°C for 1 min and 68°C for 13 min. After the cycling reaction, 1µl of 
the restriction enzyme Dpn I (provided by the kit) was added and the mixture was 
incubated at 37°C for 2 hr to specifically digest the parental non-mutated DNA 
template. The Dpn I digested products were transformed into E. coli XL1-Blue strain 
(Stratagene) for selection. The mutant plasmids were identified by DNA sequencing. 
The mutant plasmids containing the desired mutated bases were subsequently 




Table 2.4. Primers used for the mutagenesis of HLA-B*2703, B*2707 and B*2709 
Name Sense Sequences 
B*2703F            Forward 5’-GAGGGGCCGGAGCATTGGGACCGGG-3’ 
B*2703R Reverse 5’-CCCGGTCCCAATGCTCCGGCCCCTC-3’ 
B*2707-1[1]F        Forward 5’-TCCTCCGCGGGCATAACCAGTACGCCTACGACGGC-3’ 
B*2707-1[1]R Reverse 5’-GCCGTCGTAGGCGTACTGGTTATGCCCGCGGAGGAG-3’
B*2707-2[2]F        Forward 5’-CGAGGACCTGCGCTCCTGGACCGC-3’ 
B*2707-2[2]F Reverse 5’-GCGGTCCAGGAGCGCAGGTCCTCG-3’ 
B*2707-3[3]F Forward 5’-CACCCTCCAGAGCATGTACGGCTGCGACGTG-3’ 
B*2707-3[3]R Reverse 5’-CACGTCGCAGCCGTACATGCTCTGGAGGGTG-3’ 
B*2709F Forward 5’-GGTACCACCAGCACGCCTACGACGG-3’ 
B*2709R Reverse 5’-CCGTCGTAGGCGTGCTGGTGGTACC-3’ 
[1]- step one; [2]- step two; [3]- step three 
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2.8 Preparation of recombinant proteins 
Protein expression from the pET30-BirA plasmid was under the control of the tac 
promoter, which was induced using the lactose analog isopropyl β-D-thiogalactoside 
(IPTG). Protein was expressed as inclusion body and dissolved in Urea. 
 
2.8.1 Optimization of induction time for protein expression 
In the initial studies, the induction time was required to be determined for optimum 
expression of the recombinant protein.  
The construct pET30-BirA-B*2705 was used as a sample to optimize the induction 
time for B27 subtypes protein expression. E. coli BL21(DE3) competent cells were 
transformed with pET30-BirA-B*2705 by heat shock. The parental pET30-BirA 
vector was also transformed as a control for expression. Single colony was inoculated 
into 3ml LB broth supplemented with 30µg/ml kanamycin. The culture was grown at 
37°C at 220rpm overnight. Fifty microliter overnight culture was inoculated into 50ml 
kanamycin LB broth and incubated at 37°C with shaking at 220rpm until the OD600 
reached 0.6~0.8. At this point the culture was divided into 2 flasks. One was 
designated the uninduced control and the other was induced with IPTG at a final 
concentration of 1mM. Both cultures were then incubated at 37°C at 220rpm for a 
further 5 hr. Fifteen microliter of induced culture was taken every hour after IPTG 
induction for SDS-PAGE analysis. 
 
2.8.2 Up-scaled protein expression and purification 
Once the optimal induction time for protein expression had been determined, the 
protein expression could be scaled up to obtain a required amount of protein. Briefly, a 
single transformed colony was grown in 10 ml of kanamycin LB broth at 37°C with 
shaking at 220 rpm overnight. One liter of LB broth with kanamycin was then 
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inoculated with the 10ml overnight culture and grown at 37°C with shaking until 
OD600 reach 0.6~0.8. IPTG was added to a final concentration of 1mM and the 
culture was grown at 37°C for another 5 hr for protein induction. 
All subsequent steps were performed at 4°C except where indicated. Cells were 
harvested by centrifugation at 4,000× g for 10 min. The cell pellet was resuspended in 
10ml of resuspension buffer with 100µl of 0.5M DTT, 20µl of 0.1M PMSF and 10µl of 
1mg/ml pepstatin A and kept in -80°C overnight. The resuspended pellet was thawed 
at room temperature and added with 25ml lysis buffer, 1ml of 1mg/ml DNase, 200µl of 
0.5M DTT and 25µl of 2M MgCl2, followed by incubation for 20 min on ice with 
vigorous agitation. The cells were homogenized for 30 sec and added with 1ml of 
0.5M NaEDTA. The cell suspension was lysed by sonication at 10 amplitude microns 
(Am) for 5 cycles using a 5/8 inch probe, with each cycle consisting of 10 sec pulsing 
followed by 10 sec break. The cells were pelleted by centrifugation at 16,000× g for 15 
min and the supernatant were discarded. The pellets were resuspended in 150ml Wash 
Buffer I with 300µl of 0.5M DTT, 300µl of 0.1M PMSF and 150µl of 1mg/ml  
pepstatin A, followed by homogenized for 30 sec. Collected the cells by centrifugation 
at 16,000× g for 15 min and repeated the wash step three times. Discarded the 
supernatant and resuspended the pellets in 100ml Wash Buffer II with 200µl of 0.5M 
DTT, 200µl of 0.1M PMSF and 100µl of 1mg/ml pepstatin A. The cells were 
homogenized for 30 sec and collected by centrifugation at 16,000× g for 15 min. The 
supernatant was discarded and the pellets were resuspended in 10ml Urea buffer with 
20µl of 0.1M PMSF and 10µl of 1mg/ml pepstatin A and followed by homogenized for 
30 sec. The cellular debris was pelleted by centrifugation at 27,000× g for 1 hour and 
the supernatant containing proteins was transferred to a clean 10ml tube. The 
supernatant was added with 20µl of 0.1M PMSF and 10µl of 1mg/ml pepstasin A. 
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Finally, 10µl protein sample was taken out for SDS-PAGE analysis and the remaining 
supernatant was aliquoted and stored at -80°C. 
 
2.9 Protein analysis 
 
2.9.1 SDS-Polyacrylamid gel electrophoresis (SDS-PAGE) 
 
2.9.1.1 Preparation of acrylamide gels 
Separating gels with 10% and 15% of acrylamide concentrations were used in this 
study, while 5% of stacking gel was consistently applied, according to the protocols 
recommended by Sambrook et al (2001). Gels were cast using the Mini-Protein II 
electrophoresis cell apparatus (Bio-Rad) according to the manufacturer’s instruction. 
Formulations of SDS-polyacrylamide separating and stacking gels are listed in Table 
2.5. Recipes are sufficient for the preparation of 2 slab mini-gels (1mm thick and 100 
x 70mm2) and the components were mixed in the order shown. Polymerization would 
begin as soon as the N, N, N',N'-tetramethyl ethylenediamine (TEMED) (Bio-Rad) had 
been added. 
 
2.9.1.2 Sample preparation and electrophoresis 
While the stacking gel was polymerizing, the protein samples were prepared by mixed 
with 10µl of 1x SDS loading buffer, which consisted of 9.5µl of Laemmli Sample 
Buffer (Bio-Rad) and 0.5µl of β-mercaptoethanol (Bio-Rad), and the mixtures were 
boiled for 5 min. Each sample was separately loaded into the sample wells and 
electrophoresis was carried out for 1-1.5 h in the presence of 1x SDS/Glycine 
electrophoresis buffer with the constant voltage at 150v. Power supply was turned off 
when the dye front reached the bottom of the separating gel. Removed carefully from 
the electrophoresis apparatus, the gel was then stained with Commassie Blue R250 
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staining solution for 1hr with gentle agitation and destained several times with 








Table 2.5. Solutions for preparing gels for SDS-PAGE 
 
Separating gels 10% 15% 
H2O 3.9ml 2.2ml 
30% acrylamide mix (Bio-Rad) 3.33ml 5ml 
Resolving gel Buffer 2.5ml 2.5ml 
10% SDS 0.1ml 0.1ml 
10% APS 0.2ml 0.2ml 
TEMED (Bio-Rad) 10µl 10µl 
Total (for 2 gels) 10ml 10ml 
 
Stacking gels   5%  
H2O 3ml  
30% acrylamide mix 0.67ml  
Stacking gel buffer 1.25ml  
10% SDS 50µl  
10% APS 40µl  
TEMED 5µl  
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2.9.2 Native gel electrophoresis 
 
2.9.2.1 Preparation of native polyacrylamide gel 
 
Separating gel with 10% of acrylamide concentrations and 2.5% stacking gel were 
used in this study, according to the protocols recommended by Sambrook et al (2001). 
Gels were also cast using the Mini-Protein II electrophoresis cell apparatus (Bio-Rad) 
according to the manufacturer’s instruction. Formulation of native polyacrylamide 
separating and stacking gels are listed in Table 2.6. Recipes are sufficient for the 





Table 2.6. Solutions for preparing gels for native polyacrylamide gel 
 
Separating gels 10% 
H2O 7.5ml 
30% acrylamide mix (Bio-Rad) 6ml 
4× separating gel buffer 4.5ml 
10% APS 120µl 
Total (for 2 gels) 18ml 
Stacking gels 5% 
H2O 5ml 
10% acrylamide mix 2ml 
8× stacking gel buffer 1ml 
10% APS 50µl 
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2.9.2.2 Sample preparation and electrophoresis 
While the stacking gel was polymerizing, the protein samples were mixed with an 
appropriate amount of Native Sample Buffer (Bio-Rad). Each sample was separately 
loaded into the bottom of sample wells. Electrophoresis was carried out for 4~4.5 hr at 
4°C in the presence of 1x non-denaturing running buffer with the constant current at 
8mA for one gel. Power supply was turned off when the dye front reached the bottom 
of the separating gel. Removed carefully from the electrophoresis apparatus, the gel 
was then used for protein transfer. 
 
2.9.3 Protein quantitation 
The concentration of heavy chain and β2m proteins were determined by comparing the 
intensity of the protein sample with the intensity of standard bovine serum albumin 
(BSA) (Sigma, St. Louis, MO) and standard β2m (Sigma) after the proteins were 
subjected to SDS-PAGE and stained with Commassie Blue R250. BSA was diluted to 
give a range of 2µg, 4µg, 8µg and 16µg for standard and commercial β2m was diluted 
to give a range of 1µg, 2µg, 4µg, 8µg and 16µg for standard. 0.5µl, 1µl and 2µl of each 
sample protein with the standard protein were subjected to SDS-PAGE analysis. The 
protein concentration was determined by comparing the sample band intensity with 
that of standard. 
 
2.10 Peptide Synthesis 
All the 20 synthetic peptides used in this study were purchased from Alta Bioscience 
(The University of Birmingham, England), and their sequences were listed on table 2.7. 
All the peptides were dissolved in dimethysulfoxide (DMSO) at a concentration of 
25mM and stored at -20°C in small aliquots.  
 















GRAFVTIGG GRAFVTIGF  GRAFVTIGS GRAFVTIGK  GRAFVTIGD
GRAFVTIGA GRAFVTIGW  GRAFVTIGP GRAFVTIGH  GRAFVTIGE
GRAFVTIGV   GRAFVTIGT GRAFVTIGR   
GRAFVTIGL   GRAFVTIGC    
GRAFVTIGI   GRAFVTIGN    
GRAFVTIGM   GRAFVTIGQ    
   GRAFVTIGY*    
The peptides were categorized according to the position 9 residue properties 






2.11 Reconstitution of HLA-B27/peptide complex 
Refolding of the HLA-B27/peptide complex was performed by a dilution method 
(Burrows et al, 2000). Briefly, HLA-B27 heavy chain and β2-microglobulin were 
injected together with synthetic peptide (dissolved in DMSO) into a refolding buffer 
consisting of 100mM Tris (pH8.0), 400mM L-arginine, 2mM EDTA, 5mM reduced 
glutathione, 0.5mM oxidized glutathione, 0.2mM PMSF and 1µg/ml pepstatin A. The 
final concentration of the heavy chain, β2m and the peptide were 32µg/ml (1µM), 
24µg/ml (2µM) and 10µg/ml (10µM), respectively. The refolding mixture was 
incubated at 4°C for 72hr with constant stirring.  
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2.12 Gel filtration assay of HLA-B27/peptide complex 
After 72 hours incubation at 4°C, the refolded mixture was dialyzed against 20mM 
Tris (pH8.0) overnight at 4°C for buffer exchange. The refolded mixture was filtered 
through polyethersulfone (PES) membrane filter (Nalgene, Rochester, NY) and 
concentrated with centricon-30 (Millipore, Billerica, MA) to a final volume of 200µl at 
4°C. The concentrated protein was subjected to a FPLC gel filtration column Superdex 
75 column (Amersham Biosciences) equilibrated in 20mM Tris (pH8.0) at 25°C. 
Elution profiles of the proteins were monitored by UV-absorbance at 280 nm. The 
fractions were collected in 1.5 ml Eppendorf tubes, and were analyzed by SDS-PAGE 
under denaturing conditions. The fractions containing the heavy chain and light chains 
were pooled and concentrated with a centriton-30 (Millipore) to appropriate volume 
for western-blotting. 
 
2.13 Western blotting  
The refolded product was separated in 10% native polyacrylamide gel according to the 
protocol described in section 2.9.2. After electrophoresis, the separated proteins were 
transferred to a polyvinylidene difluoride (PVDF) membrane (Bio-Rad) using a Mini 
Trans-Blot Transfer Cell (Bio-Rad). Briefly, the native polyacrylamide gel was 
equilibrated in 1× transfer buffer at 4°C for 30 min with agitation. The PVDF 
membrane, filter paper (Bio-Rad) and fiber pads (Bio-Rad) were also socked in the 1x 
transfer buffer in a separate container for 30 min at 4°C. The gel sandwich was 
assembled by putting one prewetted fiber pad on the gray side of the cassette, followed 
by a sheet of filter paper, equilibrated gel, prewetted membrane, another sheet of 
socked filter paper, and the fiber pad. Air bubbles between the filter paper and gel, gel 
and membrane should be carefully rolled out using a glass tube. After the cassette was 
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placed in the tank with 1× transfer buffer, the electrophoretic transfer was performed at 
constant current at 90mA overnight at 4°C.  
After the protein was transferred to the membrane, the blotted membrane was removed 
and the marker lane was cut. Sample membrane and marker membrane were subjected 
to detection in different condition.  
The sample membrane was equilibrated in TBS I (Appendix) for 10 min and blocked 
in blocking solution I (Appendix) at room temperature (RT) for 2.5 hr with gentle 
shaking. It was subsequently washed with TTBS I buffer (Appendix) three times for 
10min each time. The membrane was incubated with the mouse anti-human HLA-
ABC antigen monoclonal antibody W6/32 (Dako A/S, Glostrup, Denmark) at 1:100 
dilution in TTBS I for 1hr with shaking at RT. After the membrane was washed with 
TTBS I by shaking for 10 min three times, the incubation with the secondary antibody, 
alkaline phosphatase conjugated goat anti-mouse IgG (Bio-Rad) at 1:2500 dilution in 
TTBS I was performed for 1 hr at RT with shaking. The membrane was finally washed 
with TTBS I buffer three times for 10 min each time and once for 10 min with TBS I 
buffer. The presence of refolded complex was then visualized with nitro blue 
tetrazolium chloride and 5-bromo-4-chloro-3-indolyl phosphate (NBT/BCIP) (Bio-Rad) 
according to manufacturer’s instruction.  
The marker membrane was equilibrated with TBS buffer II (Appendix) for 10min and 
blocked in blocking solution II for 2.5 hr at RT with shaking, followed by washing 
with TTBS buffer II (Appendix) for 10 min three times. The marker membrane was 
subsequently incubated with Avidin-AP (Bio-Rad) at 1:3000 dilution in TTBS II for 1 
hr at RT. After the marker membrane was washed thoroughly with TTBS II 10 min 
three times and once for 10 min in TBS II, the NBT/BCIP substrate was added to 
visualize the marker bands.  
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2.14 Measurement of peptide binding affinity 
Peptide binding affinity can be determined by the western blotting band intensity and 
2ml refolding mixture was used in the measurement. Briefly, 2ml of refolding mixture 
was filtered through syringe filter (Pall Corp., Ann Arbor, MI), then concentrated with 
centricon-30 (Millipore), followed by concentration in Speed-Vac to less than 20µl. 
The concentrated refolded product was subjected to western blotting analysis 
described in section 2.13.  
Monoclonal antibody W6/32 recognizes a determinant present on the HLA heavy 
chain but only when the heavy chain is in complex with β2m (Ways et al., 1983; 
Barnstable et al., 1978). Upon correct binding of peptide analogs with each B27 
subtype, a band with approximate molecular weight of 45kDa could be observed on 
the membranes. The binding affinity was then assigned a score ranging 0-5 in 
ascending order, according to the corresponding band intensity (Figure 2.1). Score 5 
was assigned to strong binding with the strongest band intensity. Score 3 and 4 were 
assigned to intermediate binding affinity. Score 2 was assigned to weak binding 
affinity. Score 1 was assigned to extremely weak binding and score 0 was assigned to 
no binding. B*2705 was chosen to set up the band intensity standard. Peptides used in 
binding affinity standard evaluation are: score 0, GRAFVTIGG; score 1, 
GRAFVTIGW; score 2, GRAFVTIGN; score 3, GRAFVTIGL; score 4, GRAFVTIGH; 
score 5, GRAFVTIGK.  
The individual binding affinity was determined by comparing the corresponding 











Figure 2.1. Characterization of the HLA-B27/peptide complex. Two milliliter of 
refolding product was used for characterization of HLA-B27/peptide complex with 
the final concentration of the heavy chain, β2m and peptide were 32µg/ml (1µM), 
24µg/ml (2µM) and 10µg/ml (10µM), respectively. Lane M: biotinylated molecular 
weight marker, with sizes (in kDa) indicated on the left margin. Binding score 0-5, 
reconstituted HLA-B27 molecules detected by mAb W6/32 with increasing binding 
affinity, scoring from 0 to 5. B*2705 was chosen to set up the band intensity 
standard.Peptides used in binding affinity standard evaluation are: score 0, 
GRAFVTIGG; score 1, GRAFVTIGW; score 2, GRAFVTIGN; score 3, 
























































The differential disease association of HLA-B27 subtypes implies that peptide binding 
specificity may be a key to the mechanism of disease association. This study aims to 
investigate the peptide binding specificity of seven differential disease association 
HLA-B27 subtypes. The construction of HLA-B27/peptide complex is very essential 
to the whole study. This schematic diagram (Figure 3.1) shows the work flow of the 
generation of the HLA-B27/peptide complex, and the results for every step will be 
described separately.  
 
3.1 Construction of plasmids  
This study employed the in vitro refolding assay to reconstitute the HLA-B27/peptide 
complex using the recombinant protein, so that the construction of the plasmid which 
encode each HLA-B27 subtype protein is essential to the success of the study. In the 
following sections, the results of each plasmid construct are explained. 
HLA-B27 molecules consist of two polypeptide chains, heavy chain and light chain. 
Heavy chain (45kDa), also called the α chain, is encoded within the HLA region. The 
light chain is non-HLA-encoded protein called β2-microglobulin (β2m, 12kDa). Heavy 
chain and β2m gene were cloned into plasmids separately.  
Plasmid pET30-BirA-β2m which contains the β2m coding gene is a generous gift from 
Professor McCluskey (University of Melbourne). This study only constructed the 
recombinant plasmids containing the heavy chain genes. 
 
3.1.1 Construction of pET30-BirA-B*2702, B*2704, B*2705 and B*2706  
Plasmids pET30-BirA-B*2702, 04, 05 and 06 contain the genes coding for the B*2702, 






























Protein expression in E. Coli.
Inclusion body preparations
Solubilize proteins in 8M urea
Refolding of B*2705/β2m/peptide
(1:2:10)
Dialysis against 20mM Tris (pH8.0) 
for buffer exchange 
FPLC gel filtration to purify the 
refolded HLA-B27/peptide complex 
Concentration of refolded complex
Western blotting detection using 
conformation specific mAb W6/32 
Figure 3.1: Schematic diagram of work flow for the construction 
of HLA-B27/peptide complex.  
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3.1.1.1 Total RNA extraction 
By using the commercial RNA isolation kit, total RNA was isolated from four EBV-
transformed B-Lymphoblastoid Cell lines, which genotype is HLA-B*2702, B*2704, 
B*2705 and B*2706. About 2µg of each RNA sample was used in RT-PCR reaction 
for cDNA synthesis.  
 
3.1.1.2 Reverse transcription – polymerase chain reaction (RT-PCR) 
Because the full length of DNA encoding the HLA-B27 heavy chain extracellular 
portion contains eight exons and seven introns, RT-PCR must be done to get the 
cDNA for the following cloning. RT-PCR was done as described in section 2.3.2.2 and 
the primers used in RT-PCR are SolB27F and SolB27R (sequence listed on table 2.3). 
Both primers were each designed with an engineered restriction enzyme digestion site 
incorporated at the 5’end of the oligonucleotides, BamH I digestion site (GGATCC) in 
SolB27F and Nhe I digestion site (GCTAGC) in SolB27R. RT-PCR products were 
subjected to 0.8% agarose gel electrophoresis and the results are shown in Figure 3.2. 
On the leftmost lane is the 1kb DNA ladder. RT-PCR product contains the region 
coding for amino acid 1-280 of the HLA-B27 heavy chain, and the expected size of 
RT-PCR product is estimated to be about 850bp. Lane 1 to 4 is the RT-PCR product of 
HLA-B*2702, B*2704, B*2705 and B*2706, respectively. Lane 5 is the negative 
control that the RT-PCR reaction was performed without the RNA sample. All the four 
RT-PCR reaction products are roughly about 850bp in length. 
 
3.1.1.3 TA cloning 
 
The RT-PCR product was subjected to gel electrophoresis and the insert DNA 
fragment with the expected size was cut and subjected to gel extraction. The purified 
DNA fragment was used in the TA cloning.  
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As described in section 2.3.3, TOPO TA cloning kit was used in the TA cloning. The 
vector pCR2.1-TOPO was ligated with the RT-PCR product and the ligated plasmids 
were transformed into competent cells E. coli BL21(DE3). After the bacterial culture 
plate was incubated at 37°C 16hrs, 15 white colonies per set of experiment were 
picked and grown in kanamycin LB broth for screening. Each colony culture was 
subjected to PCR analysis for the screening and the primer set T7F and M13R were 
used in the PCR reaction. The potential plasmids which contain the insert DNA should 
have the PCR amplification product with the expected size of about 1kb. The PCR 
amplification results of the 15 colonies from B*2702, B*2704, B*2705 and B*2706 
are shown in the Figure 3.3. The plasmids which have the PCR product with expected 
















      1500bp 
      1000bp 
        750bp 
        500bp 
 
  M         1           2           3           4          5 
Figure 3.2. Analysis of RT-PCR product in 1% agarose gel. Line M, 1kb DNA 
ladder with molecular weights (bp) indicated on the left margin. Line 1-4, HLA-
B*2702, B*2704, B*2705 and B*2706 RT-PCR product, respectively. Line 5, 




























Figure 3.3. Screening of plasmid pCR2.1-TOPO-B*2702, B*2704, 
B*2705, B*2706. Numbers indicate each screened colony. Plasmid isolated 
from each colony was analyzed by PCR amplification using the primer T7F 
and M13R. The expected size of resulted fragment is about 1kb. The DNA 
standard (M) used was 1kb DNA marker. A. pCR-TOPO-B*2702: 1kb 
fragment resulted from PCR amplification in all 15 colonies. B. pCR-TOPO-
B*2704: 1kb fragment resulted from PCR amplification in all colonies 
except colony 5. C. pCR-TOPO-B*2705: 1kb fragment resulted from PCR 
amplification in all colonies. D. pCR-TOPO-B*2706: 1kb fragment resulted 
from PCR amplification in colony 2-7, 9, 11-15. 
 
A: pCR2.1-TOPO-B*2702 
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3.1.1.4 Enzyme digestion  
After sequencing confirmation, successful pCR2.1-TOPO-B*2702, B*2704, B*2705, 
B*2706 transformants were grown up in 10ml kanamycin LB broth. Plasmid DNA 
isolated from each colony was subjected to Nhe I and BamH I digestion. The 
restriction enzyme digestion products were analyzed on a 0.8% agarose gel and the 
results are shown in Figure 3.4. The expression vector pET30-BirA was also subjected 
to Nhe I and BamH I digestion. As can be seen from the Figure 3.4, the successful 
constructed plasmids pCR2.1-TOPO-B*2702, B*2704, B*2705 and B*2706 generated 
expected ~850bp of fragments after enzyme digestion. Vector pET30-BirA also 
generated two bands, but the size of one band is only 30bp and the band was not able 
to be seen from the gel photo, so only the bigger size band is shown in the result.  
 
3.1.1.5 Construction of plasmid pET30-BirA-B*2702, B*2704, B*2705, B*2706  
To construct the plasmid pET30-BirA-B*2702, B*2704, B*2705 and B*2706, the 
B*2702/04/05/06 heavy chain DNA fragments, which were digested from the pCR2.1-
TOPO-B*2702/04/05/06 with Nhe I and BamH I , were ligated with the same enzymes 
digested pET30-BirA vector. The ligation products were transformed into the E. coli 
BL21(DE3). Ten colonies of each transformation product were picked for PCR 
screening and the primers of T7F and T7R were used in the PCR amplification. As 
shown in the Figure 3.5, for the screening of pET30-BirA-B*2702, the expected 1kb 
fragments were generated in three colonies (1, 7 and 8). The expected 1kb fragments 
were observed in three colonies (6, 8 and 9) for the screening of pET30-BirA-B*2704. 
For pET30-BirA-B*2705, seven colonies (1-4 and 6-8) had PCR amplification product 
with expected size. For pET30-BirA-B*2706, all the colonies had the expected PCR 
product. The plasmids with the expected size of PCR product were further verified to 




























Figure 3.4. Restriction enzyme digestion of plasmid construction and 
expression vector. Line M, 1kb DNA ladder with the size (bp) indicated on the 
left of the corresponding bands of the gel. Line 1-4, plasmid pCR2.1-TOPO-
HLA-B*2702, B*2704, B*2705, B*2706 digested with the Nhe I and BamH I 
and all the plasmids generated resulted fragment with the expected size of 
~850bp. Lane 5, the vector pET30-BirA digested with the Nhe I and BamH I, 
only the bigger size band was shown in the gel photo. 
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Figure 3.5. Screening of plasmids pET30-BirA-B*2702, B*2704, B*2705, 
B*2706. Numbers indicate each screened colony. Plasmid isolated from each 
colony was analyzed by PCR using the primers T7F and T7R. The expected size 
of resulted fragment is about 1kb. The DNA standard (M) used was 1kb DNA 
marker. A: pET30-Bir-B*2702, 1kb fragment resulted from PCR amplification in 
colony 1, 7 and 8. B: pET30-Bir-B*2704, 1kb fragment resulted from PCR 
amplification in colony 6, 8 and 9. C: pET30-Bir-B*2705, 1kb fragment resulted 
from PCR amplification in colony 1-4, 6, 7 and 8. D: pET30-Bir-B*2706, 1kb 
fragment resulted from PCR amplification in all 10 colonies. N, Negative control, 
PCR amplification without DNA template.  
 
A: pET30-BirA-B*2702 





















3.1.2 Construction of plasmid pET30-BirA-B*2703, B*2707, B*2709  
Plasmids pET30-BirA-B*2703/B*2707/B*2709 were generated by in vitro 
mutagenesis from pET30-BirA-B*2705 using the QuickChange Site-Directed 
Mutagenesis kit. Primers B*2703F/R and B*2709F/R were used to generate pET30-
BirA-B*2703 and pET30-BirA-B*2709 from pET30-BirA-B*2705. There are three 
steps for the generation of pET30-BirA-B*2707 plasmid. The primers HLA-B*2707-
1[1]F and HLA-B*2707-1[1]R were used in the first step site-directed mutagenesis 
reaction. After the PCR amplification and sequencing confirmation, the plasmid 
containing the desired mutation was used as template for the second step site-directed 
mutagenesis reaction. The third mutation reaction also followed the same procedure.  
The site-directed mutation PCR products were incubated with Dpn I for 1 hour, then 
transformed into E. coli XL1- Blue strain for selection. All the mutations were first 
confirmed by PCR amplification using primers T7F and T7R, and the result were 
shown in Figure 3.6. The potential plasmid should have expected 1kb PCR 
amplification fragments. As seen from the Figure 3.6, all of the colonies for screening 
had the expected 1kb PCR amplification product. All of the mutations were further 































































































Figure 3.6. Screening of plasmid pET30-BirA-B*2703, B*2707.1, B*2707.2, 
B*2707, B*2709. Numbers indicate each screened colony. Plasmid isolated from each 
colony was analyzed by PCR amplification using the primers T7F and T7R. The 
expected size of resulted fragment is about 1kb. The DNA standard (M) used was 1kb 
DNA marker. A: pET30-BirA-B*2702, 1kb fragment resulted from PCR 
amplification in all 10 colonies. B-D: pET30-BirA-B*2707.1, B*2707.2, B*2707,
mutation products of the three mutation steps from B*2705, 1kb fragment resulted 
from PCR amplification in all colonies in all the three steps. E: pET30-BirA-B*2709,
1kb fragment resulted from PCR amplification in all 10 colonies. N, Negative control, 




3.2 Preparation of recombinant protein   
3.2.1 Optimization of induction time for protein expression 
Prior to an up-scaled preparation of recombinant proteins, the protein encoded by each 
plasmid was expressed at a small scale to determine the optimum induction time. 
Plasmid pET30-BirA-B*2705 was chosen as a sample to optimize the induction time 
for all of the other HLA-B27 subtypes protein expression. pET30-BirA-B*2705 and 
pET30-BirA-β2m and the parental vector pET30-BirA were separately transformed 
into the competent cells E. coli BL21(DE3), and the induction of protein expression 
for each construct was performed in LB medium containing 30µg/ml kanamycin in the 
presence of 1mM IPTG. The expression efficiency was identified by SDS-PAGE 
analysis of 15µl culture taken over time interval after induction. Representative results 
of recombinant protein expression of pET30-BirA-B*2705 and pET30-BirA-β2m over 
time interval are indicated in Figure 3.7 A and B, respectively. The apparent size for 
B*2705 heavy chain and β2m protein is about 35kDa and 10kDa, respectively. The 
amounts of recombinant protein increased over time interval. These results showed 
that both pET30-BirA-B*2705 and pET30-BirA-β2m could be successfully induced to 
express the recombinant proteins. According to the results, 5 hours induction time was 
chosen for all the HLA-B27 subtype heavy chains and β2m up-scaled protein 
expression. 
 
3.2.2 Up-scale protein expression 
Having confirmed the successful expression and decided the optimal protein induction 
time for pET30-BirA-B*2705 and pET30-BirA-β2m at a small scale, large amounts of 
all of the B27 subtype recombinant proteins and β2-microglobulin protein were 
separately obtained in an up-scaled expression system. The induction of protein 






























































Figure 3.7: SDS-PAGE analysis of induction of recombinant protein B*2705
heavy chain and β2-m expression in E. coli over time interval. A: expression of 
pET30-BirA-B*2705 heavy chain. B: expression of pET30-BirA-β2-m. Lane M: 
Line M, Promega size marker standard with molecular weights (kDa) documented 
on the left of the corresponding bands of the gel. Lane 1-6, 15µl culture containing 
each expression plasmid collected every hour (0-5) following addition of IPTG. 
Lane 7, 15µl culture containing each expression plasmid without induction of IPTG. 
Lane 8, 15µl culture containing expression vector pET30-BirA induced by IPTG for 
5 hours. The B*2705 heavy chain and β2-m proteins are indicated by the arrows
respectively.  











3.2.3 Protein inclusion body preparation and protein quantitation 
Under IPTG induction, both heavy chain and β2m were overexpressed and appeared 
from preliminary experiments to be insoluble. Therefore, a procedure of washing and 
centrifuging is needed to achieve a high level purity of the proteins. The inclusion 
body protein was purified by taking advantage of its insolubility in aqueous and 
detergent solution. The bacterial cells were lysed by freeze and thaw method with 
lysozyme and detergent and the inclusion bodies were washed several times with 
Triton solution. The recombinant inclusion body was finally solubilized in 8M Urea. 
The concentration of the seven HLA-B27 subtype proteins was determined by 
comparing with the known concentration BSA standard and the concentration of β2m 
was determined by comparing with the commercial standard β2m. As indicated in 
Figure 3.8, all the seven B27 subtypes and β2m recombinant proteins have high 
expression in E. coli. After sonicating and washing, the purified inclusion body protein 
was over 85% pure as determined on SDS gel (Figure 3.8). The concentration of seven 
B27 subtype recombinant proteins was determined by comparing the sample band 
intensity with that of standard. HLA-B*2702/03/04/05/06 heavy chain concentrations 
are all about 8mg/ml compared to the BSA standard, while HLA-B*2707/09 are 
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Figure 3.8. Analysis of up-scaled protein expression of HLA-B27 subtypes 
and β2m by SDS-PAGE. A-G, Analysis of HLA-B*2702/03/04/05/06/07/09 
heavy chain protein on 10% SDS polyacrylamide gel. H, analysis of β2m on 15% 
SDS polyacrylamide gel. Line M, Promega size marker standard with molecular 
weights (kDa) indicated on the left of the corresponding bands of the gel. BSA 
standard with the amount of 1µg (in H), 2µg, 4µg, 8µg and 16µg are indicated; 
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3.3 Analysis of HLA-B27/peptide complex formation  
To verify if the recombinant HLA-B27 heavy chain, β2m and peptide can reconstitute 
the HLA-B27/peptide complex, the refolding product was required for further analysis 
for their identification.  
  
 
3.3.1 Analysis of HLA-B27/peptide complex formation by gel filtration on Fast 
Protein Liquid Chromatography (FPLC) 
Reconstitution of the HLA-B27/peptide complex was initiated by a dilution method 
and HLA-B*2705/peptide complex was chosen as sample for the analysis by gel 
filtration. The peptide used for reconstitution was GRAFVTIGK. Fifty milliliter of 
refolding reaction containing HLA-B*2705 heavy chain, β2m and peptide was 
performed and refolded product was concentrated to 200 µl and subjected to Superdex 
75 gel filtration column. FPLC gel filtration profile was shown in the Figure 3.9. As 
seen from the Figure 3.9.B, gel filtration can detect a peptide dependent peak.  In the 
presence of peptide, gel filtration chromatography exhibited four major peaks. The 
four peaks were eluted at 15, 17, 19 and 26 min, respectively. In the absence of peptide, 
only three major peaks could be seen from the FPLC profile at 15, 17 and 26 min 
(Figure 3.9.A). SDS-PAGE analysis of peak fractions (Figure 3.9.C) revealed that the 
peak at 15min and 17min consisted of aggregated heavy chain (Figure 3.9.C, lane 1 
and 2), and the peak at 26 min consisted of β2m (Figure 3.9.C, lane 3). A peak 
containing the HLA-B27 complex is eluted at 19 min, and SDS-PAGE analysis show 



















































Figure 3.9. Refolding of HLA-B*2705/GRAFVTIGK complex analyzed by gel 
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Figure 3.9. Refolding of HLA-B*2705/GRAFVTIGK complex analyzed by gel 
filtration FPLC and SDS-PAGE. Gel filtration FPLC profiles of HLA-B*2705 
reconstitution from recombinant heavy chain and β2m without (A) and with peptide 
(B). Peak 1 and Peak 2 correspond to heavy chain aggregates, peak 3 contains β2m 
only, and peak 4 contains the refolded HLA-B*2705/ β2m/peptide heterotrimer. C, 
SDS-PAGE analysis of the gel filtration peak fractions. Line M, size marker standard 
with molecular weights (kDa) documented on the left of the corresponding bands of 
the gel. Line 1, peak 1 at 15 min. Line 2, peak 2 at 17 min. Line 3, peak 3 at 26 min. 
Line 4, peak at 19 min. The heavy chain and the light chain of HLA-B*2705 molecule 
are marked as H and L, respectively.  
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3.3.2 Recognition of reconstituted HLA-B27/peptide complex by conformation-
sensitive mAb W6/32 
To confirm if the HLA-B27/peptide complex correspond to the classical class I 
complex found on human cell surface, the reconstituted product was performed 
western blotting using HLA-A, B, C conformation specific mAb W6/32 (Barnstable et 
al., 1978). Monoclonal antibody W6/32 recognizes a determinant present on the heavy 
chain but only when the heavy chain is in a native conformation complex with β2m and 
peptide (Barnstable et al., 1978; Ways et al., 1983). The HLA-B*2705/GRAFVTIGK 
gel filtration peak fractions eluted at 19 min was concentrated, separated on 10% 
native polyacrylamide gel and analyzed by western blotting (Figure 3.10). A band with 
approximate molecular weight of 45kDa can be observed and the result indicated that 

























Figure 3.10. Reconstituted HLA-B*2705/GRAFVTIGK complex analyzed 
by mAb W6/32. Lane M: biotinylated size marker standard with molecular 
weights (kDa) documented on the left of the corresponding bands. 
Concentrated HLA-B*2705/GRAFVTIGK complex gel filtration fraction
recognized by mAbW6/32 with the apparent size of 45kDa. 
116 
97 
  66 
45 
31 
M       HLA-B*2705 complex   
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3.3.3 Comparison of FPLC gel filtration and western blotting on the 
measurement of peptide binding affinity 
Prior to investigate the peptide binding specificity, the optimal method to measure the 
binding affinity should be established. FPLC gel filtration and western blotting were 
performed and their results were compared with each other.  
The reconstitution tests were performed using the HLA-B*2705 because this subtypes 
is the most prevalent in the population. The peptide used for refolding was HLA-B27 
restricted epitope (GRAFVTIGK) from HIVgp120 protein (Jardetzky et al., 1991). 
A series of different volume reconstitution reactions were performed using a 10-fold 
excess of peptide over heavy chain. Two milliliter, 5ml and 10ml of HLA-
B*2705/GRAFVTIGK reconstitution reactions were analyzed by gel filtration on 
FPLC and the results are shown in Figure 3.11.A-C. Ten milliliter of HLA-B*2705 
reconstitution without the peptide was used as control and the result was shown in the 
Figure 3.11.D. SDS-PAGE analysis of the peak fractions from 10ml reaction are 
shown in Figure 3.11.E. The peak fractions from 2ml and 5ml reconstitution reactions 
were too diluted to be detected from the SDS-PAGE gel, so the SDS-PAGE gels were 
not shown.  
Two milliliter reconstitution reaction of HLA-B*2705/GRAFVTIGK complex was 
concentrated to about 20µl and separated in 10% native polyacrylamide gel and all the 
western blotting steps were done according to the protocol described in section 2.13. 
The western blotting result of 2 ml reconstitution reaction showed a ~45kDa band with 
strong intensity and the result was shown in Figure 2.1 (binding score 5). The result 
suggested that 2ml reconstitution is enough for the measurement of peptide binding 






















































D: 10ml without peptide 
B: 5ml with peptide  
C: 10ml with peptide  
A: 2ml with peptide  
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Figure 3.11. Analysis of different volume reconstitution reactions of HLA-
B*2705/GRAFVTIGK by FPLC gel filtration. A-C, gel filtration FPLC 
profiles of 2ml, 5ml and 10ml reconstitution reaction with peptide, respectively. 
D, gel filtration FPLC profiles of 10ml reconstitution reaction without peptide. E, 
SDS-PAGE analysis of the 10ml reconstitution reaction gel filtration peak 
fractions. Line M, size marker standard with molecular weights (kDa) indicated 
on the left of the corresponding bands. Line 1and 2, peak at 15 and 17min
corresponding to heavy chain aggregates. Line 3 and 4, peak at 19 and 20 min, 
containing the refolded HLA-B*2705/ β2m/peptide heterotrimer. Line 5 and 6, 
peak at 26 and 29 min, containing β2m only. The heavy chain and the light chain 
of HLA-B*2705 molecule are marked as H and L, respectively.  
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3.4 Modulation of P9 Specificity by HLA-B27 Polymorphisms  
After the two methods were compared with each other, western blotting was chosen to 
investigate the peptide binding specificity. The reason for choosing western blot will 
be discussed in the next chapter. Peptide specificity is modulated by HLA 
polymorphism through affecting the structure of pockets in the antigen binding site 
which accommodate peptide residue. HLA-B27 subtypes have the same structure in 
the pocket B. Much of the B27 subtype polymorphism are located in the C/F pocket 
and can influence the preference for C-terminal peptide residue. This may be a key to 
the linkage of HLA-B27 subtypes to disease. Therefore, the peptide GRAFVTIGK and 
its P9 substituted analogues were used to investigate the peptide binding specificity at 
P9 residues for seven HLA-B27 subtypes (HLA-B*2702/03/04/05/06/07/09).   
Two milliliter reconstitutions of seven HLA-B27 subtypes with the peptide 
GRAFVTIGK and its 19 P9 substituted analogues were performed and their western 
blotting results were shown in the Figure 3.12. The effects of variability at P9 residue 
on peptide binding were assessed by measuring the binding affinity of each 
reconstituted complex. Their binding affinity were assessed by comparing its western 
blotting band intensity with the standard described in section 2.14, and the results are 
summarized in Figure 3.13. Previous studies indicated that the peptides naturally 
presented by HLA-B27 subtypes bound to HLA-B27 subtypes in vitro with strong or 
intermediate binding affinity (Galocha et al., 1996; Garcia et al., 1997c). Based on 
these observations, the results of present study were categorized into two groups. The 
strong or intermediate binding affinity was classified to positive group, while the weak 
or no binding was classified to negative group. The preference on the P9 residue based 




3.4.1 Binding of peptides with C-terminal aromatic residue 
This study agreed with the previous studies that the peptides with those C-terminal 
aromatic residues found in the natural ligands bound to HLA-B*2702/04/05/06/07 
with strong or intermediate binding affinity. B*2703 bound the peptide with C-
terminal Phe and Tyr with strong or intermediate binding affinity. B*2709 bound the 
peptides with C-terminal Phe with intermediate binding affinity, and bound the peptide 
with C-terminal Tyr with weak binding affinity, but did not bind to the peptide with P9 
Trp. Tyr was less favored in B*2706/07/09 (116Tyr/His) than in B*2702/03/04/05 
(116Asp). 116Asp located in the β-pleated sheet implies an acidic charge. Changing of 
116Tyr/His to 116Asp improved the binding with C-terminal Tyr.  
 
3.4.2 Binding of peptides with C-terminal negatively charged residue 
All of the data from sequencing of pooled and individual peptide or mass spectrometry 
analysis indicate that negatively charged residues were not allowed at P9 for the seven 
subtypes. In this study subtype B*2702/03/04/09 didn’t bind the peptides with these C-
terminal residues, and B*2705 and B*2707 bound these peptides with weak binding 
affinity. One exception is that the peptide with P9 Asp bound to B*2706 with 
intermediate binding affinity. Compared with B*2704, B*2706 lost an acidic charge in 
the F pocket as a consequence of the 116 change (Asp116 in B*2704, Tyr116 in B*2706). 
This change makes the pocket F in B*2706 is less negatively charged, so that it may 
bind the negatively charged amino acid.  
 
3.4.3 Binding of peptides with C-terminal positively charged residue 
Previous studies showed that B*2705 bind peptide with C-terminal basic residues, 
whereas there was no peptide with P9 basic residue found in the peptide repertoire for 
the subtype B*2706 and B*2707. This was confirmed in the present study by showing 
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that peptide with P9 basic residue bound to B*2705 with strong or intermediate 
binding affinity, while these peptides bound to B*2706 and B*2707 with weak binding 
affinity or can not bind to these two subtypes. B*2702 and B*2704 didn’t bind the 
peptide with P9 Lys and Arg, but they still can bind the peptide with P9 His. Different 
from previous data, B*2709 bound the peptides with C-terminal Lys, His and Arg with 
intermediate binding affinity, while B*2703 bound these peptides with strong binding 
affinity.  
 
3.4.4 Binding of peptides with C-terminal aliphatic residue 
Compared to other amino acid group, B27 subtypes have more tolerance in 
accommodation of C-terminal aliphatic residues. Agreed with previous data that there 
were no natural peptide with C-terminal Gly in the peptide repertoires, Gly was 
detrimental to all these B27 subtypes peptide binding in this study. The peptides with 
C-terminal Leu, Ile, Ala, Val and Met bound to B*2704/05/06/07/09 with strong or 
intermediate binding affinity. B*2702 bound the peptide with C-terminus Leu, Ile and 
Met with intermediate binding affinity. B*2703 bound the peptide with C-terminal 
residue Leu, Ile, Val and Met with intermediate binding affinity.  
 
3.4.5 Binding of peptides with C-terminal polar uncharged residue 
There were no peptides with the C-terminal polar, uncharged amino acid detected in 
the peptide repertoire from the seven B27 subtypes except one peptide with C-terminal 
Cys was found in B*2709 peptide repertoire. In this study, B*2702 and B*2703 can’t 
bind any peptide with C-terminal polar, uncharged residue, whereas B*2705 bound 
peptide with C-terminal Ser, Thr, Cys, Asn and Gln, but with weak binding affinity. 
The peptide with C-terminal Thr bound to B*2704/06/07/09 with intermediate binding 
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affinity. B*2709 bound the peptide with C-terminal Ser, Cys and Gln with 
intermediate binding affinity.  
In summary, our results showed that B27 subtypes have different capability in 
accommodation of the peptides with various C-terminal residues, but all of them prefer 
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Figure 3.12: Western Blotting analysis of different HLA-B27/GRAFVTIGX (X, 
any natural amino acid) reconstituted complex. Lane M: biotinylated size marker 
standard with molecular weight (kDa) indicated on the left margin. The rest of the 
lanes represent the binding result of each HLA-B27 subtypes reconstituted with the 
P9 substituted peptide analogues. The letter above each lane represents the peptide
GRAFVTIGX carrying the corresponding C-terminal amino acid. The letter is the 





































































































































Figure 3.13: Binding Affinity of seven B27 subtypes with GRAFVTIGX (X, 





















































Figure 3.13: Binding Affinity of seven B27 subtypes with GRAFVTIGX (X, 
any natural amino acid). The letter in the category axis is the one-letter symbol of 
natural amino acid and represents the peptide GRAFVTIGX carrying the 
corresponding C-terminal amino acid. The binding affinity was assigned a score 
ranging 0-5 in ascending order, according to the corresponding western-blotting 
band intensity. Score 5 was assigned to strong binding affinity with the strongest 
band intensity. Score 4 and 3 were assigned to intermediate binding affinity. Score 
2 was assigned to weak binding affinity. Score 1 was assigned to extremely weak 
binding affinity and score 0 was assigned to no binding.  
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Table 3.1. Comparison of peptide P9 specificity from natural ligands and refolded 
ligands. 
 
1a:  C-terminal anchor motifs - aromatic R group 
 Natural ligands*   
Refolded ligands 
(This study)  Consensus 




Weak or no 
binding (-)  + - 
B*2702 F, Y, W   F, Y, W   F, Y, W  
B*2703 F, Y, W   F, Y   F, Y  
B*2705 F, Y W  F, Y W  F, Y W 
B*2709 F, Y W  F W, Y  F W 
B*2704 F, Y W  F, Y W  F, Y W 
B*2706 F W, Y  F W, Y  F W, Y 
B*2707  W, Y, F   W, Y, F   W, Y 
 
1b:  C-terminal anchor motifs – negative charge R group 
 Natural ligands*   
Refolded ligands 
(This study)  Consensus 




Weak or no 
binding (-)  + - 
B*2702  E, D   E, D   E, D 
B*2703  E, D   E, D   E, D 
B*2705  E, D   E, D   E, D 
B*2709  E, D   E, D   E, D 
B*2704  E, D   E, D   E, D 
B*2706  E, D  D E   E 
B*2707  E, D   E, D   E, D 
 
1c:  C-terminal anchor motif - positively charged R group 
 Natural ligands*   
Refolded ligands 
(This study)  Consensus 




Weak or no 
binding (-)  + - 
B*2702  K, H, R  H K, R   K, R 
B*2703 R K, H  K, H, R   R  
B*2705 R, K, H   K, H, R   K, H, R  
B*2709 R K, H  K, H, R   R  
B*2704 R K, H  H K, R   K 
B*2706  K, H, R   K, R, H   K, R, H 




1d:  C-terminal nonpolar, aliphatic R group 
 Natural ligands*  
Refolded ligands 
(This study) Consensus 





no binding  
(-) 
+ - 
B*2702 L, I G, A, V, M L, I, M G, A, V  L, I G, A, V 
B*2703 L G, A, I, V, M L, I, M, V G, A  L G, A 
B*2705 L, I, A, V, M G L, I, M, A, V G  L, I, A, V, M G 
B*2709 L, I, A, V, M G L, I, M, A, V G  L, I, A, V, M  
B*2704 L, I, A, V G, M L, I, M, A, V G  L, I, A, V G 
B*2706 L, I, A, V G, M L, I, M, A, V G  L, I, A, V G 
B*2707 L, V G, A, I, M L, I, M, A, V G  L, V G 
 
 
1e: C-terminal polar, uncharged R group   
 Natural ligands*   
Refolded ligands 
(This study)  Consensus 




Weak or no 
binding (-)  + - 
B*2702  S, P, N, Q, T, C   S, P, N, Q, T, C   S, P, N, Q, T, C 
B*2703  S, P, N, Q, T, C   S, P, N, Q, T, C   S, P, N, Q, T, C 
B*2705  S, P, N, Q, T, C   S, P, N, Q, T, C   S, P, N, Q, T, C 
B*2709 C S, P, N, Q, T  T, S, Q, C P, N   P, N 
B*2704  S, P, N, Q, T, C  T S, P, N, Q, C   S, P, N, Q, C 
B*2706  S, P, N, Q, T, C  T S, P, N, Q, C   S, P, N, Q, C 
B*2707  S, P, N, Q, T, C  T S, P, N, Q, C   S, P, N, Q, C 
 
*natural ligands data set is from sequencing of pooled and individual peptide or mass 
spectrometry analysis. The letter in the table is the one-letter symbol of amino acid and 
represents the peptide with the corresponding C-terminal amino acid. For natural 
ligands, ‘+’, peptide with those C-terminal residues were found in the peptide 
repertoire; ‘-’, peptide with those C-terminal residues were not found in the peptide 
repertoire. For refolded ligands, ‘+’, peptide with those C-terminal residues bound to 
the subtypes with strong or intermediate binding affinity; ‘-’, peptide with those C-
terminal residues didn’t bind to the peptide or bound to the subtypes with weak 
binding affinity. In consensus, ‘+’, amino acid found in both the natural and refolded 
ligands for the positive group; ‘-’, amino acid found in both the natural and refolded 





























HLA-B27 molecules show a remarkable association with ankylosing spondylitis (AS) 
(Brewerton et al., 1973a), reactive arthritis (ReA) (Brewerton et al., 1973b) and other 
spondyloarthropathies (SpA) (Paul 2000). Strong evidences have shown that HLA-
B27 molecules are directly involved in the disease pathogenesis (Lopez 1994, Lopez 
1995), yet the mechanism remains a mystery.  
The differential association of B27 subtypes with the AS disease emphasizes the need 
for a detailed understanding of peptide binding specificity and its modulation by 
polymorphism, so that it can facilitate the identification of the potential arthritogenic 
peptides that may trigger the disease (Benjamin & Parham, 1990). Peptide specificity 
is modulated by HLA polymorphism through affecting the structure of pockets for 
peptide side chains in the antigen binding site. All of the B27 subtypes differ from one 
another in one or few amino acid residues occupying defined positions in the peptide 
binding groove (Lopez 1998). Most of the variations are located in the C/F pocket, 
which accommodate the carboxyl terminus of the peptide, so that amino acid changes 
at these pockets alter the specificity of the C-terminal residue.  
This study systematically explored the effects of variability at the peptide C-terminal 
anchor residue on its binding to differential disease associated HLA-B27 subtype 
(HLA-B*2702, B*2703, B*2704, B*2705, B*2706, B*2707, B*2709) and added some 
information to the HLA-B27 peptide specificity and its disease association.  
 
4.1 Cloning of HLA-B27 heavy chain plasmid 
In vitro refolding assay use the recombinant protein to investigate the peptide binding 
specificity of HLA-B27, so the genes encoding HLA-B27 heavy chain and light chain 
were cloned and the protein were expressed.  
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HLA-B27 heavy chain gene consists of eight exons and seven introns (Weiss et al., 
1985), so RT-PCR was performed to get the cDNA which encode the whole reading 
frame of HLA-B27 heavy chain protein. HLA-B27 heavy chain contains three portions: 
extracellular, transmembrane and cytoplasmic segments. Among the three segments, 
only the extracellular part participates in the interaction with β2m and peptide, so only 
this part was cloned to be investigated. Using the primers SolB27F and SolB27R, 
protein coding region of the entire extracellular domain plus 5 amino acids length 
transmembrane domain of HLA-B27 heavy chain (amino acid 1~280) was amplified. 
Since primer SolB27F and SolB27R were engineered with the BamH I and Nhe I 
restriction enzyme site, respectively, the RT-PCT product was flanked with the two 
enzyme digestion site and can be used in the subsequent enzyme digestion.  
RT-PCR product was cloned into pCR2.1-TOPO vector and white/blue selection and 
sequencing were performed to obtain the proper clone. TA cloning enhances the 
insertion efficiency of PCR products into a plasmid vector, but the pCR2.1-TOPO 
vector is not an expression vector, so the PCR product was needed to subcloned into 
the expression vector for protein expression. The vector pET30-BirA was used as an 
expression vector and can be induced protein expression under the induction of IPTG.  
Since we only have EBV-transformed B-Lymphoblastoid Cell lines which genotype is 
HLA-B*2702/04/05/06, the other three HLA-B27 subtypes heavy chain clones HLA-
B*2703/07/09 had to be obtained using the site-directed mutagenesis from pET30-
BirA-B*2705. Sequencing must be carried out to confirm if the transformatant 
contained the desired mutations. After the desired clones were obtained, the 





4.2 Protein expression of HLA-B27 heavy chains and β2 - microglobulin 
The vector pET30-BirA contains the T7 promoter and lac operon and can be induced 
protein expression under IPTG induction. The expression of protein increases over 
time interval. Considering the time consumption and protein amount, 5 hours was 
chosen as the protein induction time.  
As has frequently been observed in other over-expression of HLA molecules, such as 
HLA-A2 (Garboczi et al., 1992), HLA-Cw3 (Kim et al., 1997) and HLA-B8 (Burrows 
et al., 2000), all of the HLA-B27 heavy chain proteins and β2m were highly expressed 
in an insoluble form within the bacterial cell, which allowed a procedure of washing 
and centrifuging to achieve a high level purity of the proteins. The insoluble protein 
can be purified by taking advantage of its insolubility in aqueous and detergent 
solution and can usually be dissolved in strong denaturants (here 8M Urea). High 
purity and large amount of protein can be obtained after the treatment of washing and 
dissolving in denaturants. This facilitated the next step HLA molecule reconstitution.  
 
 
4.3 Reconstitution of HLA-B27 molecules 
HLA molecules could not reconstitute a stable complex without a peptide or with an 
irrelevant peptide (Silver et al., 1991; Garboczi et al., 1992). Only some combinations 
of peptides and histocompatibility antigen can reconstitute stable HLA molecules in 
vitro, and the peptide enhances reconstitution or may be bound to the reconstituted 
HLA molecules (Silver et al., 1991). Using this property, the reconstitution method 
could be used to determine if a peptide is restricted or bound to certain HLA molecules.  
In this study, HLA-B27 molecules were obtained by refolding the recombinant B27 
heavy chain protein under dilution conditions by the removal of denaturant in the 
presence of β2m and a HLA-B27 restricted peptide. The reconstituted HLA-
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B*2705/GRAFVTIGK appeared as a peak on FPLC gel filtration chromatography. 
Analysis of the complex by SDS-PAGE revealed that it was composed of the HLA-
B*2705 heavy chain and β2m. The reconstituted HLA-B*2705/GRAFVTIGK complex 
can be recognized by the conformation sensitive monoclonal antibody W6/32 
indicating that the recombinant complex contains native epitopes, consistent with the 
presence of a correctly folded molecular complex. 
HLA-B*2705 molecular can be successfully reconstituted in the presence of correct 
peptides. The control refolding experiment was performed in the absence of peptide 
and also analyzed by FPLC gel filtration, but there was no complex peak observed 
(Figure 3.9.A). This result agreed with the previous finding that the reconstituted HLA 
complex is not stable and disappear by ~24 hours when the complex was collected and 
concentrated in the absence of a peptide (Garboczi et al., 1992).  
Reconstitution of HLA molecules in the presence of a peptide is a straightforward in 
vitro method for determining the peptide binding affinity. Because of starting with 
denatured heavy chain, there is no activity in partially purified E. coli inclusion bodies 
that can cause the HLA heavy chain to bind to β2m (Parker et al., 1992), therefore, 
reconstitution is strictly dependent on the addition of synthetic peptides.  
By applying reconstitution method large amount of HLA/peptide complex will be 
obtained, which will accelerate biochemical, immunological and crystallographic 
studies that have been limited by the small amount of protein available from 
homozygous human cell lines. Large amounts of specific HLA-peptide complexes will 
also be helpful in examining recognition by specific CTLs through the potential 






4.4 Comparison of gel filtration and western blotting on peptide binding affinity 
 
Both of FPLC gel filtration and western-blotting can be performed to measure the 
peptide binding affinity.  
As shown in the series of different volume reconstitution reaction gel filtration profile 
(Figure 3.10), a peptide dependent peak was observed only in the presence of a peptide. 
But the peak was not detectable in the 2ml reconstitution and this is maybe because the 
reconstituted HLA-B27/peptide complex was too little to be detected by FPLC gel 
filtration. For 5ml reconstitution product, there was a small peak which can be detected 
by gel filtration, but from the analysis of peak fraction on SDS-PAGE, there was no 
band observed. This is maybe because the peak fraction is too diluted to be detected. 
There was an apparent peptide dependent peak in the 10ml reconstitution gel filtration 
profile and the peak fractions were also detectable in the analysis of SDS-PAGE. So 
for gel filtration, 10ml reconstitution product is the minimum volume for detection.  
Western-blotting is also a helpful method for the detection of the reconstituted 
HLA/peptide complex. Two milliliter reconstituted product is enough for the detection 
and the western blotting band has strong intensity. Two parameters were employed to 
confirm that the bands turned out in western blot were the correctly refolded HLA-
B27/peptide complex - the use of HLA-A, -B, -C conformation dependent monoclonal 
antibody W6/32, and the size of the refolded product electrophorized on native 
polyacrylamide gel.  
From gel filtration and SDS-PAGE analysis, it was known that the reconstituted 
complex contained the HLA-B27 heavy chain and light chain, but it cannot confirm 
that the refolded product is correctly folded. A further concentration of peak fraction 
and western blotting are required to verify the HLA-B27 complex. Ten milliliter 
reconstitution reaction is the minimum volume for the analysis by gel filtration, so that 
Discussion 
 106
increase the time and cost for protein concentration compared with only 2ml 
reconstitution reaction needed for western-blotting. Western blotting can screen many 
reactions and compare the results in one membrane at the same time. Taking into 
account all of the factors, western blotting was chosen for the measurement of peptide 
binding affinity and 2ml of each reaction was performed to do the measurement.  
 
4.5 Modulation of P9 Specificity by HLA-B27 Polymorphisms  
HLA-B27 encompasses a group of twenty-eight subtypes. These subtypes are known 
to have nearly identical B pocket but differ from each other in several amino acids 
located predominantly within the peptide binding groove. Most of the polymorphic 
residues cluster in the C/F pocket, which anchor the peptide C-terminal residue (P9), 
and greatly influence the peptide specificity. This could correlate with the differential 
disease association of various B27 subtypes. 
HLA-B27 polymorphism contribute to the shape and chemical characteristics of the 
pockets within the binding region and these features can play a role in distinguishing 
between peptides of similar length but different sequence. Almost all polymorphic 
amino acid side chains in the binding domain are oriented inwards toward the region 
containing peptide. This suggests that the major role of polymorphism is to regulate 
the binding of peptides, rather than to directly affect interaction with the T cell receptor 
(Alvarez, 1997).  
Arg at P2 is a rather rigidly maintained feature of B27 binding peptides, and previous 
study has shown change of Arg to other amino acid drastically impaired the binding 
even other primary and secondary anchor positions were occupied by preferred 
residues (Villadangos et al., 1995, Lamas et al., 1999). On the contrary, C-terminal 
residues were more variable. The nature of C-terminal residue is probably one of the 
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major factors determining the observed differences among subtype-bound peptide 
repertoires because of the variable C/F pocket among these subtypes.  
The comparative studies of the seven HLA-B27 subtypes complexed with peptide 
GRAFVTIGK and its analogues described here indicated that different B27 subtypes 
have different preference on the C-terminal residues. The Gly at P1 and the Ala at P3 
may have a contribution to the binding, but their effects are minimized due to the small 
sizes and neutral chemical characters. B*2705 has different binding affinity with the 
peptides GRAFVTIGK and its P9 substituted analogues, which is in agreement with 
the thermodynamic properties of HLA-B*2705 molecules reported before (Dedier et 
al., 2000). B*2705 strongly bound the peptide GRAFVTIGK, which is consistent with 
previous result that employed cellular binding assay to test the peptide binding affinity 
(Villadangos et al., 1995). For the peptide GRAFVTIGK, at position 9, the 20 natural 
amino acids were ranked in a hierarchy among the seven HLA-B27 subtypes. The 
hierarchy of P9 residues were summarized from the consensus of Table 3.1 according 
to the number of HLA-B27 subtypes which can accommodate a specific amino acid. 
Leucine is clearly the most preferred residue at position 9 followed by other aliphatic 
amino acid side chains (Figure 4.1). Aromatic residues are also preferred by most of 
B27 subtypes at P9. The highest ranking amino acid in the hierarchy is best to the 
reconstitute the HLA-B27/peptide complex, while a low-ranking amino acid would be 
expected to have less contribution to the peptide binding or may prevent peptide 
binding. HLA-B27 subtypes have big tolerance in accommodation of C-terminal 
aliphatic residues compared to other residue. This study showed that the peptides with 
C-terminal Met can bind to all the seven B27 subtypes, but the peptides with C-
terminal Met were not observed in the eluted natural peptide repertoire. Met has 
similar properties with Leu and Ile considering form size and hydropathy, so the 
Discussion 
 108
peptide with P9 Met has high probability to bind to all subtypes as the peptides with C-
terminal Leu and Ile, like the result observed in this study. 
This study showed that B*2702, B*2704 and B*2705 bound C-terminal Tyrosine 
strongly, while B*2706 and B*2709 displayed poor affinity for C-terminal Tyrosine. 
This is suggestive of the potential arthritogenic peptide with C-terminal Tyr. B*2709 
differs from B*2705 by a single amino acid substitution (Asp116 in B*2705, His116 in 
B*2709), and B*2706 differs from B*2704 by two amino acid changes (Asp114His 
and Tyr116Asp). Residue 116 are located in F pocket and the change in this pocket 
presumably account for the differences in the peptides specificity, thus account for the 










P1 P3 P4 P5 P6 P7 P8P2 P9
L,  I,  V,  A, M,  F, Y,   H, K, R 
Aliphatic Aromatic Basic 
R 
Basic 
Figure 4.1. The hierarchy of anchor residue at P9 for seven HLA-B27 
subtypes. P1-P9 represent the peptide residue positions. P2 is consistent Arg 
in all the seven B27 subtypes, but P9 is more variable. The hierarchy of the P9
residues accommodated by the seven B27 subtypes were summarized from the 
consensus of table 3.1. The ranking is according to the number of HLA-B27 
subtypes which can accommodate a specific amino acid. The letter is the one-




B*2705 and B*2703 are structurally close alleles, differing at a single residue at 
position 59 in pocket A of the peptide binding groove. This could influence peptide 
binding without major alterations in the nature of peptide anchor residues. But the 
peptide specificity differences between these two subtypes in accommodation of 
residues at P9 were surprising because they have identical C/F pockets. B*2705 can 
bind the peptide with C-terminal polar uncharged amino acid, although the binding 
affinity is weak, but B*2703 can’t bind these kind of peptides. These data demonstrate 
that substitutions at position 59 in B*2703 still have some effect on the peptide 
binding affinity, especially when the peptide C-terminal residue is a non-preferred 
residue. This study showed B*2703 and B*2705 can bind some of the peptides with 
similar binding affinity, supporting the hypothesis that B*2703 presents only a subset 
of B*2705 peptides (Colbert et al., 1994, Villadangos et al., 1994).  
In our studies, HLA-B27 polymorphisms have relatively moderate influences on 
binding specificity at P9. This explains the significant overlap of B27 subtype-bound 
peptide repertoires. Nevertheless, it seemed that residue 77/97 polymorphism could 
influence suitability of C-terminal residues for HLA-B27 subtypes. Pro was only 
suitable for B*2704/06 (77S, 97N), although with weak binding affinity, while Arg 
was only favored in B*2703/05/09 (77D, 97N). Binding of either of these residues 
were not observed in B*2702 (77N, 97N), B*2707 (77D, 97S). The binding of Pro 
required simultaneous presence of 77S and 97N, whereas that of Arg required 
simultaneous presence of 77D and 97N. For disease-unassociated subtypes 
(B*2706/09), there were no common features that were not shared by other disease-
associated subtypes. It is possible that their differential association with AS correlates 
not only with their differential acceptance of C-terminal residues, but also with a more 
Discussion 
 110
complex modulation of their peptide repertoires, affecting at least also P1 and P3 
residues.  
Some unique findings were also observed in this study. For B*2702, it can bind the 
peptide with C-terminal His. This could be due to B*2702 unique polymorphism in F 
pocket (77N, 80I, 81A). The 77N ensures that F pocket contains fewer negative charge 
compared to B*2705.  Histidine has an imidazole group and it is the only standard 
amino acid having an ionizable side chain with a pKa near neutrality. Its weaker 
charge property than Lys and Arg may cause B*2702 binding to the peptide 
GRAFVTIGH. B*2709 bound the peptide with C-terminal Lys, His and Arg and 
*2707 can bind the peptide with C-terminus Ala and Ile other than Leu and Val in this 
study. Although these residues are not B27 subtypes motif, from our result, it is 
important to note that peptide containing non-preferred residues as C-terminus may 
also bind to these subtypes. More extensive sequencing is required to investigate the 
natural peptides repertoire to find out if the natural ligands contain these non-preferred 
residues as C-terminus.  
As the effect of a mutation on peptide binding depends on the structural context where 
it occurs, a same change may have different functional consequences. Structure of the 
epitope is often altered upon binding of the peptide to a different subtype. This can be 
either because the conformation of the peptide is different when bound to different 
subtypes or because the residues that are changed among subtypes directly alter the 
structure of the complex and its interaction with TCR. So even if a peptide binds to 
various B27 subtypes, its immunogenicity or antigenicity maybe be different in each 
context. Thus, HLA-B27 polymorphism could influence antigen presentation in ways 
more than simply peptide binding. 
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There is remarkable agreement between the previous published motifs established by 
the sequencing and mass spectrometry analysis of B27-bound peptide repertoire and 
our refolding assay. The two different approaches strengthen the empirical data on the 
specificity of C-terminal residues that occupy the different B27 subtype C/F pocket. 
This also indicated that refolding assay involving the recombinant heavy chain and 
light chain protein can mostly reflect the physiological conditions of HLA complex 
formation, so that it should be a valuable method for measuring peptide binding 
affinity.  
 
4.6 The doubt on the hypothesis of arthritogenic peptide  
Another aspect of this study concerns the association of HLA-B27 with ankylosing 
spondylitis (AS). One approach to the study of HLA-disease association is to 
investigate the differences between the peptide binding specificity of disease-related 
subtype and non-disease related subtypes (Wucherpfennig et al., 1995). The classical 
arthritogenic peptide hypothesis suggests the peptide putatively involved in HLA-B27-
restricted pathogenetic T-cell responses should presumably be arthritogenic when 
presented by various disease associated subtype, but not in the context of those not 
associated with disease (Ramos et al., 2002). Previous studies have suggested that 
putative arthritogenic peptide was likely to have Arg 2 and lack a basic C-terminal 
residue, since this motif was not found among natural ligands from the disease 
associated subtypes (B*2702, B*2704 and B*2707). In addition, neither B*2706 nor 
B*2709 showed a C-terminal Tyr motif suggested that arthritogenic peptide might 
have a C-terminal Tyr. But this was challenged by the absence of this motif among 
natural ligands of B*2707 (Tieng et al., 1997).  
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This study showed that some HLA-B27 subtypes can bind the same peptides with 
similar binding affinity. From this study results, there is no apparent binding feature 
difference between the disease associated and non-associated subtypes. Previous 
studies also indicated extensive overlap among subtype-bound peptide repertoires 
(Marti et al., 2001; Sesma et al., 2002; Ramos et al. 2002b) The overlap of peptide 
repertoires helps to limit the search for putative arthritogenic peptides within the 
relative small subsets whose binding pattern correlates with the subtype associated 
with AS.  The structural features of arthritogenic peptides can be outlined based on 
those motifs shared by differentially bound ligands. However, two alternatives are 
possible that would drastically affect the nature of arthritogenic peptides and possible 
strategies for their identification. First, an arthritogenic peptide could be a natural 
ligand of disease-associated subtypes, but not of those not associated with AS (Ramos 
et al., 2002a). Second, an arthritogenic peptide would be presented in vivo by disease-
associated subtypes at very low levels. In this view, B*2706 and B*2709 individuals, 
would be tolerized against this self-antigen as a result of thymic deletion of 
autoreactive T cells. Thus, autoimmunity triggered by external challenge with a 
crossreactive antigen would take place only for subtypes with low expression of the 
arthritogenic peptide. This possibility was suggested in a recent report (Fiorillo et al., 
2000). It is conceivable that a shared ligand of HLA-B27 subtypes might be relevant to 
arthritogenesis only when presented by some of them (Ramos, 2002a), but one recent 
study suggested that differential association of HLA-B27 with SpA is more likely 
related to differentially bound peptides than to altered antigenicity of shared ligands 
(Montserrat et al., 2003). Further studies are required to substantiate the correlation of 
B27 subtype bound peptide repertoires with their differential disease association.  
The arthritogenic peptide hypothesis does not clearly account for the CD4 T-cell 
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dependency of the disease in transgenic rats (Breban et al., 1996), or for occurrence of 
arthritis in β2m-deficient mice (Khare et al., 1995). In contrast, the difficulty of finding 
putative arthritogenic peptides is no argument against this hypothesis, because it is 
clear from the complexity of HLA-B27-bound peptide repertoires and the subtleties of 
molecular and antigenic mimicry that the search is far from straightforward. However, 
increasing knowledge of B27-bound peptides, which has been facilitated by 
development in mass spectrometry, of the nature of peptide-MHC-TCR interactions, 
provided by numerous X-ray diffraction analyses and T-cell functional studies, are 
expected to provide new insights into the nature of putative arthritogenic peptides and 
their role in the pathogenesis of SpA.  
 
4.7 Future considerations 
This study only investigated the effect variability at P9 residue on the peptide binding 
affinity. Arginine at P2 is a rather rigidly maintained feature of HLA-B27 peptide. 
However, residues at other positions variously interact with HLA binding pockets, 
therefore, single amino acid substitutions at every position could alter the entire 
formation of a bound peptide modulating the binding affinity (Madden et al., 1993). 
Therefore, the effect of variability at other positions on peptide binding affinity also 
should be explored. This study only used one HLA-B*2705 restricted epitope and its 
analogues to study the peptide binding affinity. An important issue is whether the 
hierarchy of residue at P9 obtained in this study is same for all peptides to the first 
approximation. So more peptides may be chose for further investigation.  
This study employed an in vitro refolding assay to analyze the suitability of different 
C-terminal residues for various B27 subtypes. Although the refolding assay is a 
reliable and reproducible method to investigate peptide binding with MHC molecules, 
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it does not fully mimic the complicated in vivo process of peptide loading, which is a 
highly complicated process requiring physical association of proteasome, TAP 
transporter, several chaperones, and the natural microenvironments. It’s possible that 
subtypes discriminate more strictly among peptides in vivo, based on differences in the 
dissociation rates that not detected in our assay. So we can employ the cellular binding 
assay to confirm this study’s results in future. 
A useful method to define the rules governing peptide binding is to elucidate the HLA 
molecule 3-D structure. Until now only the structures of HLA-B*2705 and HLA-
B*2709 have been revealed. Using the in vitro refolding method, large amount of 
HLA-B27 molecules can be obtained for crystallography. This will facilitate the 
understanding of interaction between HLA-B27 molecules and peptides.  
Although the association of HLA-B27 with AS and other spondyloarthropathies (SpA) 
has been discovered for almost 30 years, not only the mechanism of this association 
remains unknown, but there is still no agreement on the correct working hypothesis, 
This leads us to think that the mechanism of association of HLA-B27 to SpA may not 
simple, and perhaps no single-sided hypothesis might fully explain the pathogenic role 
of HLA-B27.  
The major problem associated with studying the pathogenesis of AS, and its related 
SpA disorders, lies in the analysis of the T-cell response in the absence of a known 
target antigen. An important goal for future research is to define the exact nature of the 
target antigen, assuming that the underlying mechanism is an antigen-specific immune 
response. Therefore, identification of the peptides that are derived from pathogens and 
that are recognized in association with the susceptible HLA-B27 subtypes is very 
important.  
New candidate genes that interact with HLA-B27 in the pathogenesis of the disease 
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also need to be found. Although strong evidence suggests that additional genes exist, 
and that they play important role in the development of the disease, their exact nature 
and function remain unknown (Reveille et al., 2001). The characterization of these 
putative genes and a better knowledge of the factors that trigger the disease should 
allow us to predict which HLA-B27 positive individual will develop SpA, and they 
might provide the key to develop effective prevention and treatment strategies for AS 
and other SpA disorders.  
In summary, our study has defined some major rules governing P9 residue preference 
for seven B27 subtypes and has described how these features are modulated by B27 
polymorphism. The results of the in vitro refolding assay in this study are in strong 
agreement with the accumulated data from sequencing of bound natural ligands. There 
is enhanced control and consistency in the refolding assay which will provide an 
excellent platform for future studies of peptide-HLA interactions. The differential 
association of B27 subtypes with AS is unlikely to be explained solely by its peptide-
binding properties. Further studies are required to substantiate the correlation of B27 
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Appendix I: Growth media 
 
1: LB(Luria-Bertani) media for E. coli BL21(DE3) (per liter) 
 Tryptone (Difco)                              10 g 
 Yeast extract (Difco)                                       5 g 
 NaCl (Merck)                                                      5 g 
LB media was made up to 1 liter with distilled water. The PH of the solution was 
adjusted to 7.5. LB agar was prepared by adding 15g Agar (Oxiod) per liter of LB 
media. The media was sterilized by autoclaving at 121ºC for 15 minutes. 
 
2: NZY+ Broth for E. coli XL1-Blue (per liter) 
 NZ amine (Sigma) 10 g 
 Yeast extract (Difco) 5 g 
 NaCl (Merck) 5 g 
Media was made up to 950ml with distilled water. The pH of the solution was adjusted 
to 7.5 with NaOH. The media was sterilized by autoclaving at 121ºC for 15 minutes. 
Prior to use, add the filter sterilized solution 12.5ml of 1M MgCl2, 12.5ml of 1M 
MgSO4 and 20ml of 20% (w/v) glucose solution to the sterilized media.  
 
3: SOC meida (per liter) 
 Tryptone (Difco)                              20 g 
 Yeast extract (Difco)                                       5 g 
 NaCl (Merck)                                                      0.58 g 
Media was made up to 1 liter with distilled water. The pH of the solution was adjusted 
to 7.0 with NaOH. The media was sterilized by autoclaving at 121ºC for 15 minutes. 
Prior to use, add the filter sterilized solution 10ml of 1M MgCl2 and 10ml of 20% (w/v) 




Appendix II:  Buffers and Stock Solutions 
 
1: Solution used for preparation of competent cells 
 
TfB I (per 200ml) 
KAc (Sigma)                        0.59g (final 30mM) 
 KCl (Merck) 1.49 (final 100mM) 
CaCl2‧2H2O (Merck)              0.3g (final 10mM) 
Glycerol                           30ml (final 15% v/v) 
MnCl2‧2H2O (Merck)         1.62g (final 50mM) 
The solution was made up to 200ml with distilled water. Filtered and stored at 4°C. 
 
TfB II (per 100ml) 
NaMOPs (Sigma)                                    0.21g (final 10mM) 
CaCl2‧2H2O                 1.1g (final 75mM) 
KCl                                      0.07456 (final 10mM) 
Glycerol                                    15ml (final 15% v/v) 
The solution was made up to 100ml with distilled water. Filtered and stored at 4°C. 
 
2: Solution used for cloning and expression 
Kanamycin stock (60mg/ml) 
Kanamycin (Sigma) 0.6g   
Dissolved in a final volume of 10ml of sterile double-distilled water. Filter-sterilized 




IPTG (Bio-Rad) 2.38g  
Dissolved in final volume of 10ml of double-distilled water. Filter-sterilized through 
0.22µm membrane. Dispensed into 1ml aliquots and stored at −20°C. 
X-gal (40mg/ml) 
X-gal (Bio-Rad)  40mg 
Dissolved in 1ml of DMF in a polypropylene tube wrapped in aluminium foil and 
stored at -20°C. 
 
2: Buffers and solutions for preparation of recombinant protein 
Dnase I stock (1mg/ml) 
 1M Tris-HCL, pH7.5 0.4ml (final 20mM) 
 MgCl2 (Merck) 1.9mg (final 1mM) 
 Glycerol (Sigma) 10ml 
 DNase I (Sigma) 20mg 
The solution was made up to 20ml with double-distilled water. Dispensed into 1ml 
aliquots and stored at −20°C. 
DTT stock (0.5M) 
 DTT (Sigma)                         3.85mg            
Dissolved in 50ml double-distilled water. Dispensed into 1ml aliquots and stored at 
−20°C. 
PMSF stock (0.1M) 
 PMSF (Sigma) 0.87mg 
Dissolved in 50ml isoproponal. Dispensed into 1ml aliquots and stored at −20°C. 
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pepstatin A stock (1mg/ml) 
 pepstatin A (Sigma) 10mg 
Dissolved in 10ml ethanol. Dispensed into 0.5ml aliquots and stored at −20°C. 
Resuspension buffer (per liter) 
           1M Tris-HCl, pH8.0         50ml  
           Sucrose (Sigma)                                          0.25g 
           0.5M NaEDTA                                                         2ml 
           Sodium Azide (Sigma)                                            1g 
The buffer was made up to l liter with double-distilled water and stored at 4°C. 
Lysis Buffer (per liter) 
 1M Tris-HCl (pH 8.0)                                                 50ml  
 Triton X-100 (Sigma)                                                 10ml 
 Sodium deoxycholate (Sigma)                                    10mg 
NaCl                                                                  5.8g 
 Sodium Azide (Sigma)                                                1mg 
The buffer was made up to l liter with double-distilled water and stored at 4°C. 
 
Wash Buffer 1 (per liter) 
 1M Tris-HCl (pH 8.0)                                               50ml 
Triton X-100 (Sigma)                                                 5ml 
NaCl                                                                  5.8g 
0.5M NaEDTA                                                          2ml 
Sodium Azide (Sigma)                                                1mg 
The buffer was made up to l liter with double-distilled water and stored at 4°C. 
Appendices 
 141
Wash Buffer 2 (per liter) 
1M Tris-Cl, pH8.0 50ml 
0.5M NaEDTA 2ml 
Sodium Azide (Sigma)                                               1mg 
The buffer was made up to l liter with double-distilled water and stored at 4°C. 
Urea Buffer (8M) (per 500ml) 
MES (Sigma)                                                          2.44g 
Urea (Merck)                                                   240g  
0.5M NaEDTA                     10ml 
The buffer was made up to 500ml with double-distilled water and stored at 4°C. 
 
3: Solutions used for SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
30% acrylamide solution                                 Bio-Rad 
Resolving gel Buffer: 
 Tris base (Sigma)                                           36.3g (final 1.5M) 
This solution was made up to 200ml with distilled water to give a final concentration 
of 1.5M and the pH adjusted to 8.8 with concentrated HCl. Stored at room temperature. 
Stacking gel buffer 
 Tris base (Sigma)                       12g (final 0.5M) 
This solution was made up to 200ml with distilled water to give a final concentration 
of 0.5M and the pH adjusted to 6.8 with concentrated HCl. Stored at room temperature. 
10% Ammonium persulphate (APS)  
          Ammonium persulphate (Bio-Rad)                0.1g 
The solution was made up to 1ml with sterile distilled water and stored at 4℃. 
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10% SDS (Sodium dodecyl sulfate) 
 SDS (Sigma)                                                              10g 
The solution was made up to 100ml with sterile distilled water and stored at room 
temperature. 
10 x SDS/Glycine electrophoresis buffer 
 Tris 30.3g (final 250mM) 
 Glycine (Merck) 144g (final 1.92M) 
 SDS 10g 
The solution was made up to 1000ml with sterile distilled water and the pH adjusted to 
8.3 with HCl. Stored at room temperature and diluted to 1x before use. 
 
4: Solutions used for native Polyacrylamide gel electrophoresis 
30% acrylamide solution                                Bio-Rad 
 
10% acrylamide solution                                 
 
 Acrylamide (Sigma) 10g 
 N, N’-methylenebisacrylamide (Sigma) 2.5g 
 
The solution was made up to 100ml with double-distilled water and filtered through 
0.45µm membrane. The solution was stored in a brown bottle at 4 .℃  
4 x separating gel buffer 
 
 Tris 18.2g (final 1.5mM) 
 TEMED (Bio-Rad) 0.23ml 
This solution was made up to 100ml with distilled water to give a final concentration 
of 1.5M and the pH adjusted to 8.9 with concentrated HCl. The solution was stored in 
a bottle wrapped with aluminum foil at room temperature. 
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8 x stacking gel buffer 
 Tris 6g (final 0.5M) 
 TEMED (Bio-Rad) 0.46ml 
This solution was made up to 100ml with distilled water and the pH adjusted to 6.9 
with concentrated HCl. The solution was stored in a bottle wrapped with aluminum 
foil at room temperature. 
10 x non-denaturing running buffer 
 Tris 6g (final 50mM) 
 Glycine (Merck) 28.8g (final 384mM) 
The solution was made up to 1 liter with distilled water and the pH adjusted to 8.3 with 
concentrated HCl. Stored at 4℃ and diluted to 1x before use. 
Sample loading buffer for SDS-PAGE Bio-Rad 
Sample loading buffer for native-PAGE Bio-Rad  
Staining Solution  
 Coomassie Brilliant blue R250 (Bio-Rad)    0.6g 
 Methanol (Merck)                                                      250ml 
 Glacial acetic acid (Merck)                                    50ml 
The solution was top up to 500ml with distilled water. The solution was stored in a 
bottle wrapped with aluminum foil at room temperature. 
Destaining solution  
 Methanol (Merck)                                                      250ml 
 Glacial acetic acid (Merck)                                50ml 




5: Solution used for western blotting 
10 x Transfer buffer 
 Tris 30.3g (final 250mM) 
 Glycine 144g (final 1.92mM) 
The solution was made up to 1 liter with distilled water and the pH adjusted to 8.3 with 
HCl. Stored at 4℃ and diluted to 1 x before use. 
Blocking solution I (per 50ml) 
 BSA (Sigma) 1.5g 
 Gelatin (Bio-Rad) 0.125g 
The solution was made up to 50ml with TBS I before use. 
Blocking solution II (per 50ml)  
 Gelatin (Bio-Rad) 1g 
Gelatin was melted in 50ml TBS I by boiling in a microwave oven. Cool down before 
use. 
TBS I 
 Tris 2.42g (final 20mM) 
 NaCl 8.7g (final 150mM) 
The solution was made up to 1 liter with sterile distilled water and the pH adjusted to 
7.4 with HCl. Stored at room temperature.  
TBS II 
 Tris 2.42g (final 20mM) 
 NaCl 29g (final 500mM) 
The solution was made up to 1 liter with sterile distilled water and the pH adjusted to 




 Tris 2.42g (final 20mM) 
 NaCl 8.7g (final 150mM) 
 Tween-20 (Bio-Rad) 500µl 
The solution was made up to 1 liter with sterile distilled water and the pH adjusted to 
7.4 with HCl. Stored at room temperature. 
TTBS II 
 Tris 2.42g (final 20mM) 
 NaCl 29g (final 500mM) 
 Tween-20 500µl 
The solution was made up to 1 liter with sterile distilled water and the pH adjusted to 
7.4 with HCl. Stored at room temperature. 
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Appendix III       Cloning vectors used in this study 
 
                                                                                                                                    
 
CAG GAA ACA GCT ATG ACC ATG ATT ACG CCA AGC TTG GTA CCG AGC TCG GAT CCA CTA 
GTC CTT TGT CGA TAC TGG TAC TAA TGC GGT TCG AAC CAT GGC TCG AGC CTA GGT GAT 
 
                                                               
 
GTA ACG GCC GCC AGT GTG CTG GAA TTC GCC CTT             AAG GGC GAA TTC TGC 
CAT TGC CGG CGG TCA CAC GAC CTT AAG CGG GAA             TTC CCG CTT AAG ACG 
 
                                                                                   
 
AGA TAT CCA TCA CAC TGG CGG CCG CTC GAG CAT GCA TCT AGA GGG CCC AAT TCG CCC  




TAT AGT GAG TCG TAT TAC AAT TCA CTG GCC GTC GTT TTA CAA CGT CGT GAC TGG GAA 
























Figure 7.1. Map pf the pCR®2.1-TOPO vector. The map shows the main features of 
this vector and the sequence of restriction sites surrounding the TOPO cloning site. 





























ATT AAT ACG ACT CAC TAT AGG GGA ATT GTG AGC GGA TAA CAA TTC CCC TCT AGA AAT  
TAA TTA TGC TGA GTG ATA TCC CCT TAA CAC TCC CCT ATT GTT AAG GGG AGA TCT TTA  
 
 
AAT TTT GTT TAA GTT TAA GAA GGA GAT ATA CAT ATG GGA TCC GGT ACC CTG GTC GTA 
TTA AAA CAA ATT GAA ATT CTT CCT CAT TAT GTA TAC CCT AGG CCA TGG GAC CAG CAT 
         
 
TAC ACA ACA GCT AGC GGG TCC GGG CTG CAT CAT ATT CTA GAT GCA CAG AAA ATG GTG 
ATG TGT TGT CGA TCG CCC AGG CCC GAC GTA GTA TAA GAT CTA CGT GTC TTT TAC CAC 
 
 
TGG AAT CAT CGT TAA AAG CTT GCG GCC GCA CTC GAG CAC CAC CAC CAC CAC CAC TGA  
ACC TTA GTA GCA ATT TTC GAA CGC CGG CGT GAG CTC GTG GTG GTG GTG GTG GTG ACT 
 
 
GAT CCG GCT GCT AAC AAA GCC CGA AAG GAA GCT GAG TTG GCT GCT GCC ACC GCT GAG 
CTA GGC CGA CGA TTG TTT CGG GCT TTC CTT CGA CTC AAC CGA CGA CGG TGG CGA CTC 
 
 
CAA TAA CTA GCA TAA CCC CTT GGG GCC TCT AAA CGG  
GTT ATT GAT CGT ATT GGG GAA CCC CGG AGA TTT GCC  
 
                                  
                                   
 
 
















Figure 7.2. Map of the pET-30-BirA vector. The map shows the reading frames and main 
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